

1 **The assembly of neutrophil inflammasomes during COVID-19 is mediated by type I**
2 **interferons**

3 **Luz E. Cabrera^{1,*}, Suvi T. Jokiranta^{2,3}, Sanna Mäki¹, Simo Miettinen^{1,4}, Ravi Kant^{1,4,5},**
4 **Lauri Kareinen^{1,4}, Tarja Sironen^{1,4}, Jukka-Pekka Pietilä^{6,7}, Anu Kantele^{6,7}, Eliisa**
5 **Kekäläinen^{2,3,10}, Hanna Lindgren¹¹, Pirkko Mattila¹¹, Anja Kipar^{4,8,9}, Olli Vapalahti^{1,4,10}**
6 **and Tomas Strandin¹**

7

8 ¹Viral Zoonosis Research Unit, Medicum, Department of Virology, University of Helsinki, Helsinki,
9 Finland.

10 ²Department of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland.

11 ³Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki,
12 Finland.

13 ⁴Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland.

14 ⁵Department of Tropical Parasitology, Institute of Maritime and Tropical Medicine, Medical University
15 of Gdansk, 81-519 Gdynia, Poland.

16 ⁶Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki,
17 Finland.

18 ⁷Meilahti Vaccine Research Center MeVac, Department of Infectious Diseases, Inflammation Center,
19 Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

20 ⁸Laboratory for Animal Model Pathology, Institute of Veterinary Pathology, Vetsuisse Faculty,
21 University of Zurich, 8057 Zurich, Switzerland.

22 ⁹Department of Infection Biology & Microbiomes, Institute of Infection, Veterinary and Ecological
23 Sciences, University of Liverpool, Liverpool L3 3RF, UK.

24 ¹⁰Division of Virology and Immunology, HUSLAB Clinical Microbiology, HUS Diagnostic Center,
25 Helsinki University Hospital, Helsinki, Finland.

26 ¹¹Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.

27 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

28 **Abstract**

29 The severity of COVID-19 is linked to excessive inflammation. Neutrophils represent a critical
30 arm of the innate immune response and are major mediators of inflammation, but their role in
31 COVID-19 pathophysiology remains poorly understood. We conducted transcriptomic
32 profiling of neutrophils obtained from patients with mild and severe COVID-19, as well as
33 from SARS-CoV-2 infected mice, in comparison to non-infected healthy controls. In addition,
34 we investigated the inflammasome formation potential in neutrophils from patients and mice
35 upon SARS-CoV-2 infection. Transcriptomic analysis of polymorphonuclear cells (PMNs),
36 consisting mainly of mature neutrophils, revealed a striking type I interferon (IFN-I) gene
37 signature in severe COVID-19 patients, contrasting with mild COVID-19 and healthy controls.
38 Notably, low-density granulocytes (LDGs) from severe COVID-19 patients exhibited an
39 immature neutrophil phenotype and lacked this IFN-I signature. Moreover, PMNs from severe
40 COVID-19 patients showed heightened nigericin-induced caspase1 activation, but reduced
41 responsiveness to exogenous inflammasome priming. Furthermore, IFN-I emerged as a
42 priming stimulus for neutrophil inflammasomes, which was confirmed in a COVID-19 mouse
43 model. These findings underscore the crucial role of neutrophil inflammasomes in driving
44 inflammation during severe COVID-19. Altogether, these findings open promising avenues for
45 targeted therapeutic interventions to mitigate the pathological processes associated with the
46 disease.

47

48 **Keywords:** inflammasome, neutrophils, COVID-19, type I interferon, inflammation, innate
49 immunity.

50 **Introduction**

51

52 Severe COVID-19 is characterized by a dysregulated immune response with an excessive
53 production of pro-inflammatory cytokines and chemokines. Type I interferons (IFN-I) are
54 critical antiviral cytokines in the innate immune responses against viral infections, drawing
55 particular attention amidst the COVID-19 pandemic (1–3). While the IFN-I response helps to
56 limit virus replication (3), its prolonged and uncontrolled activation is detrimental to the overall
57 health of the patient (4). As part of the pro-inflammatory response, neutrophils are rapidly
58 recruited to the site of infection in response to SARS-CoV-2 infection (5, 6). Prominent
59 neutrophil recruitment in severe COVID-19 is associated with an increased number of
60 immature low-density granulocytes (LDGs) in the circulation (7–9). The increased production
61 and subsequent early release of immature cells from the bone marrow occurs in response to
62 emergency myelopoiesis (9). This process is initiated by the body to enable the recruitment of
63 innate immune cells into the tissues and to replenish the depleted leukocyte pool, in an effort
64 to combat viral infections including SARS-CoV-2 (10). However, the premature release of
65 these cells could be associated with the increased degranulation and formation of neutrophil
66 extracellular traps (NETs) reported during SARS-CoV-2 infection, to which LDGs have a
67 higher propensity than polymorphonuclear cells (PMN) (5, 6, 11).

68

69 Neutrophils are involved in several aspects of inflammatory processes, including the release of
70 reactive oxygen species (ROS) and other pro-inflammatory mediators such as Interleukin-6
71 (IL-6) and IL-8. In addition, recent reports on COVID-19 highlight that neutrophils could be a
72 major source of inflammasome derived IL-1 β , which has been implicated as a substantial
73 contributor to COVID-19 pneumonia (12). Inflammasomes are intracellular multiprotein
74 complexes involved in the inflammatory response. In the presence of a pathogen, antigen

75 recognition by the immune system triggers the assembly of the inflammasome, a step known
76 as the first signal. This is followed by the recruitment of adaptor molecules that activate NOD-
77 like receptor (NLR) family members and the binding of the apoptosis-associated speck-like
78 protein (ASC), finally activating the inflammasome complex (13). The triggered assembly of
79 this complex is known as the second signal. Studies have shown that SARS-CoV-2 infection
80 induces significant inflammasome activation in circulating and lung-infiltrating myeloid cells,
81 such as monocytes and neutrophils (14–17). However, while the precise mechanism by which
82 inflammasomes are activated in monocytes/macrophages is well established, less is known
83 about molecular mechanisms of inflammasome formation in neutrophils. Thus, this study
84 investigates the inflammasome formation in neutrophils during COVID-19 in more detail, also
85 focusing on the different developmental stages of these cells. In addition, a recently established
86 COVID-19 mouse model served to further explore the role of IFN-I in neutrophil
87 inflammasome assembly.

88 **Materials and methods**

89 **Patient population**

90 Adult clinical patients with confirmed COVID-19 (RT-PCR positive for SARS-CoV-2) at
91 Helsinki University Hospital (HUU) (hospitalized: n = 34; outpatients: n = 8) were enrolled in
92 the present study. Blood samples were collected during hospitalization for the severe COVID-
93 19 group, and after confirmation of diagnosis for the mild COVID-19 outpatient group.
94 Samples for RNA sequencing were collected in 2020 and representing infections by the original
95 and early SARS-CoV-2 variants, whereas samples for *ex vivo* culture experiments were
96 collected in 2021-2022 likely representing infections by omicron subvariants of SARS-CoV-
97 2. As controls, healthy blood donors were included for RNA sequencing (n = 7, age 57 ± 7 ,
98 male/female 3/4) and *ex vivo* culturing experiments (n = 9, age 38 ± 14 , male/female 4/5). The
99 study was approved by the Ethics Committee of the Hospital District of Helsinki and Uusimaa
100 (HUS/853/2020, HUS/1238/2020). All volunteers gave a written informed consent, in
101 accordance with the Declaration of Helsinki. For clinical correlation analysis, severe COVID-
102 19 patients were further categorized by severity based on their need for hospitalization and
103 oxygen supplementation, as described previously (7). For each patient, medical history and
104 clinical data were collected through retrospective patient record review and are presented for
105 the severe COVID-19, hospitalized patients in Table 1 and as previously described (7).
106 Calprotectin was measured from serum (diluted 1:1000) by ELISA, according to the
107 manufacturer's protocol (calprotectin/S100A8 DuoSet kit, R&D systems).

108 **Isolation of granulocytes from human blood**

109 Blood samples from COVID-19 patients and healthy controls (HC) were collected in EDTA
110 vacutainer tubes and transported to the laboratory. Peripheral blood mononuclear cells

111 (PBMCs) or polymorphonuclear cells (PMNs) were isolated from whole blood by density
112 gradient centrifugation using either Ficoll-Paque Plus (GE Healthcare) or Polymorphprep
113 (Axis-Shield) respectively, following standard procedures including the use of 2 mM EDTA in
114 PBS and red blood cell lysis with ACK lysis buffer (Lonza by Thermo Fisher). Subsequently,
115 isolation of CD66⁺ granulocytes (low-density granulocytes, LDGs) from the PBMC fraction
116 was performed using the CD66abce MicroBead Kit (Miltenyi Biotec, Germany) with an MS
117 column, according to the manufacturer's instructions. Both the positively selected CD66⁺
118 LDGs and the isolated PMNs were then washed and counted, using a TC20TM Automated Cell
119 Counter (Bio-Rad Laboratories, Inc.) with trypan blue staining for dead cell exclusion. All
120 described procedures in this section were done at room temperature. An aliquot of cells was
121 lysed in Trizol reagent (Thermo Fisher Scientific, USA) and stored at -80°C for later extraction
122 of total RNA and subsequent RNA sequencing (RNA-seq) analysis.

123 **Caspase1 activity**

124 Caspase1 activity was assessed in isolated cells after 2 h of culture (1 million cells/ml) using
125 the caspase-Glo[®]1 inflammasome assay (Promega) according to the manufacturer's protocol,
126 with 2.5 μM nigericin (Invivogen) treatment as the activator. The resulting luminescence was
127 measured by a Hidex Sense microplate reader (Hidex).

128 **Soluble factor stimulation assays**

129 Isolated granulocytes from HC and COVID-19 patients were cultured at 2 million cells/ml in
130 RPMI 1640 supplemented with 10% fetal bovine serum (R10) at 37°C . Cells were primed (1st
131 signal) with either LPS (20 ng/ml, Sigma Aldrich) or IFN-I (combination of 2.7×10^4 IU/ml
132 IFN- α and IFN- β , Immunotools) for 4 h, followed by activation (2nd signal) by 2.5 μM nigericin
133 or monosodium urate crystals (MSU, 100 $\mu\text{g}/\text{ml}$, Invivogen) for an additional 4 h. For the 24
134 h stimulation experiments, nigericin was added to the cultured cells, in the presence or absence

135 of inflammasome inhibitors MCC995 (2 µg/ml) and Ac-YVAD-FMK (20 µg/ml, both from
136 Invivogen). Cells were pelleted by centrifugation at 400 G for 5 min and stored in Trizol at –
137 80°C for later RNA extraction whereas supernatants were used to measure IL-1β, IL-18,
138 myeloperoxidase (MPO) and IL-8 by ELISAs according to the manufacturer’s protocols
139 (DuoSet kits from R&D systems). LDH was measured in supernatants using Cyquant LDH
140 cytotoxicity assay (ThermoFisher). HL-60 cells (ATCC #CCL-240) were activated similarly
141 to neutrophils after a 5-day differentiation period induced by 1 % DMSO.

142

143 **Virus propagation**

144 The SARS-CoV-2 hCoV-19/Finland/THL-202117309/2021 (delta strain B.1.617.2) and the
145 mouse-adapted strain MaVie (18) were propagated in VeroE6-TMPRSS2 cells (kidney
146 epithelial cells expressing the transmembrane protease serine 2) (19) grown in DMEM
147 supplemented with 10% inactivated FCS, 100 IU/mL Penicillin, 100 µg/mL Streptomycin and
148 2 mM L-glutamine at 37°C. The virus was purified from supernatants by ultracentrifugation
149 (SW28 rotor, 27,000 rpm, 90 min, +4 °C) through a 0.22 µm-filtered 30% ultra-pure sucrose
150 cushion (in PBS), to obtain virus preparations free of cell culture contaminants. Virus titers
151 were calculated by the median tissue culture infectious dose (TCID₅₀) after assessing
152 cytopathic effects by crystal violet staining of cell cultures infected for 5 days with serially
153 diluted virus.

154

155 **RNA sequencing**

156 Neutrophils isolated from different cohorts comprised three PMN groups (severe COVID-19,
157 mild COVID-19, and healthy controls), and one LDG group (given that these cells were rare
158 in mild COVID-19 patients and HC, only LDGs from patients with severe COVID-19 were
159 included).

160 cDNA synthesis from total RNA was performed according to Takara SMARTseq v4 Ultra-low
161 input RNA kit for Sequencing user manual (Takara Bio, Mountain View, CA, USA) followed
162 by Illumina Nextera XT Library preparation according to Illumina Nextera XT Reference
163 Guide (Illumina, San Diego, CA, USA). UDI index setup was used for the Nextera XT libraries.
164 Library quality check was performed using LabChip GX Touch HT High Sensitivity assay
165 (PerkinElmer, USA) and libraries were pooled based on the concentrations acquired from the
166 assay. The pooled libraries were quantified for sequencing using KAPA Library Quantification
167 Kit (KAPA Biosystems, Wilmington, MA, USA) and sequenced on the Illumina NovaSeq6000
168 system for 200 cycles using S1 flow cell (Illumina, San Diego, CA, USA). Read length for the
169 paired-end run was 2x101 bp.

170

171 **RNA data analysis**

172 Principal Component Analysis (PCA) and enrichment analyses were obtained using
173 ExpressAnalyst (20). Briefly, PCA was performed to identify patterns in the data and reduce
174 the dimensionality of the dataset, where the top principal components were selected based on
175 the percentage of variance explained. For enrichment analyses, Gene Set Enrichment Analysis
176 (GSEA) and Over-Representation Analysis (ORA) were performed on the top 5000 DE genes
177 identified by DESeq2 (adjusted P value < 0.05, log₂FC >1) (20). GSEA was used to identify
178 enriched signaling pathways using the Reactome database, while ORA was used to identify
179 enriched pathways using the KEGG database. The resulting p-values were corrected for
180 multiple testing using the Benjamini-Hochberg method, and pathways with a corrected p-value
181 <0.05 were considered significant.

182 To visualize the expression patterns of the differentially expressed (DE) genes, the data was
183 analyzed using the AltAnalyze software (21), which selected the top 118 genes based on
184 correlation and determined the heatmap clustering, using the Euclidean distance metric and the

185 complete linkage method. Then, the obtained heatmap was re-generated using heatmapper.ca
186 (22) for better visualization.

187 CIBERSORTx, a machine learning algorithm that infers cell type proportions using a reference
188 gene expression matrix of known cell types (25) was used to perform RNA-seq deconvolution
189 on the gene expression data to estimate the abundance of immune cell types in the samples
190 (23). The signature matrix used was taken from Lasalle *et al.* (8). This reference matrix made
191 use of a published whole-blood single-cell dataset (9), and included the main immune cell
192 types: monocytes, NK cells, T lymphocytes, B lymphocytes, plasmablasts and neutrophils, the
193 latter subclassified into mature and immature. The smaller subsets of granulocytes (eosinophils
194 and basophils) are not considered separately and are most likely categorized as neutrophils in
195 the bulk data deconvolution. Nonetheless, the resulting cell type proportions were used to
196 compare the immune cell composition between groups.

197 Additionally, the determination of sample purity (>65% identified as neutrophils) served as a
198 limiting parameter for the visualization of differentially expressed inflammasome related genes
199 from the RNA sequencing results, which were selected and graphed in a heatmap using
200 heatmapper.ca (22), clustered by complete linkage and ordered by Spearman's rank.

201

202 **Volcano Plots**

203 To visualize differentially expressed (DE) genes between groups from human and mice RNA-
204 seq results previously identified by DESeq2, a volcano plot was generated using GraphPad
205 Prism. Genes with a P-adjusted value (padj or FDR) <0.05 were considered significant.
206 Similarly, RNA sequencing data from GSE93996 (24) was reanalyzed, and all DE genes in
207 ATRA-differentiated HL-60 cells were visualized in a volcano plot.

208

209

210 **Single cell transcriptomics data analysis**

211 This study made use of the “COVID-19 Immune Atlas: integration of 5 public COVID-19
212 PBMC single-cell datasets” available online (25). This standardized data collection contains
213 cells from different assays (10x 3' v2, 10x 3' v3, 10x technology and Seq-Well) and consists of
214 a total of 239,696 cells from the peripheral blood, 3,693 of which are neutrophils. These
215 neutrophils were further subclassified as mature (59%) and immature (41%), based on the
216 immune atlas predetermined cell classes. This was confirmed by a CD16b expression in mature
217 neutrophils, and a higher CD66b expression in the immature population. This data was obtained
218 from and analyzed in the Chan Zuckerberg CELLxGENE platform (25).

219

220 **Reverse transcription and quantitative PCR (RT-qPCR) for human selected human** 221 **genes**

222 Total RNA was extracted from unstimulated or *ex vivo* stimulated PMNs using the Trizol
223 reagent (Invitrogen, USA) according to the manufacturer’s protocol. Subsequently, cDNA
224 synthesis was performed using the RevertAid RT Reverse Transcription Kit (Thermo
225 Scientific, USA) as per the manufacturer's instructions. Quantitative PCR (qPCR) was
226 performed using the Stratagene model (Agilent Technologies) and SYBR Green/ROX master
227 mix (Thermo Scientific, USA). The primer sequences for qPCR are presented in
228 Supplementary Table S1.

229 Primer specificity was confirmed using melting curve analysis and dissociation curves. The
230 relative expression levels of the genes of interest were calculated using the $2^{-\Delta\Delta CT}$ method
231 and normalized to the expression of the housekeeping gene GAPDH. Baseline gene expressions
232 of unstimulated samples were statistically assessed using the Mann-Whitney test, while the
233 two-way ANOVA Tukey’s multiple comparisons test was performed for the *ex vivo* stimulated
234 samples.

235 **Mouse infections**

236 Experimental procedures were approved by the Animal Experimental Board of Finland (license
237 number ESAVI/28687/2020). Female BALB/c mice (Envigo, Indianapolis, IN, USA; 7 to 8
238 weeks, n = 36 in total) were transferred to the University of Helsinki biosafety level-3 (BSL-
239 3) facility and acclimatized to individually ventilated biocontainment cages (ISOcage;
240 Scanbur, Karl Sloanestran, Denmark) for 7 days with *ad libitum* water and food (rodent pellets).
241 For subsequent experimental infection, the mice were placed under isoflurane anesthesia and
242 inoculated intranasally with 50 μ L of SARS-CoV-2 MaVie strain (5×10^5 TCID₅₀/animal) or
243 PBS (mock-infected control). Daily weighting of all mice was performed, and their well-being
244 was carefully monitored for signs of illness (e.g., changes in posture or behavior, rough coat,
245 apathy, ataxia). Euthanasia was performed by cervical dislocation under terminal isoflurane
246 anesthesia. All animals were dissected immediately after euthanasia, and the lungs were
247 sampled for multiple downstream analyses. The infections were performed as 3 separate
248 experiments (exp) with 12 mice each: 1) Exp 1 included 8 mice infected with MaVie and 4
249 mock infected mice. At 2 days post infection (dpi), 4 infected and the mock infected mice were
250 euthanized; the remaining infected mice were euthanized at 4 dpi. The right lung was sampled
251 for virus-specific RT-qPCR (1/5) and neutrophil isolation (4/5), the left lung was fixed for
252 histological and immunohistochemical examination. 2) Exp 2 included 8 infected and 4 mock
253 infected mice of which half were euthanized at 2 dpi and 4 dpi, respectively. From these mice,
254 both lung lobes were subjected to neutrophil isolation. 3) Exp 3 included 8 mice that were
255 infected and immediately inoculated intraperitoneally with 250 μ g of anti-mouse IFNAR-1 (n
256 = 4) or IgG1 isotype control (n = 4) (Bio-X-Cell, New Hampshire, USA), and 4 mock-infected
257 animals. All mice were euthanized at 2 dpi. Each 1 1/5 of the left lobe was processed for virus-
258 specific RT-qPCR and histology and immunohistochemistry respectively. The remaining
259 approx. 80% of the lungs served for neutrophil isolation.

260 **Neutrophil isolation from mouse lungs**

261 Neutrophil isolation was performed from the lungs of all mice. The dissected lung tissue was
262 chopped into small pieces using scissors and enzymatically digested with a cocktail of Liberase
263 (50 ug/ml; Roche #05401020001 from Merck) and DnaseI (100 ug/ml; Roche #11284932001
264 from Merck) in RPMI-1640 for 30 min at 37 °C. The resulting homogenate was diluted 10-
265 fold in R10 and passed through a 70 µm Cell strainer (Pluriselect) to obtain a single-cell
266 suspension. Neutrophils were isolated by positive selection using Ly6G-binding magnetic
267 beads and MS columns according to the manufacturer's recommendations (Miltenyi Biotec).
268 Neutrophils were isolated with a purity exceeding 95% based on flow cytometry analysis of
269 Ly6G expression.

270

271 **RNA sequencing of mouse neutrophils**

272 Mouse neutrophils were isolated, lysed in Trizol (Thermo Scientific) and the RNA extracted
273 in the liquid phase using chloroform. RNA isolation was carried out using the Rneasy micro
274 kit (Qiagen). Isolated RNA (1 ng) underwent whole transcriptome sequencing with
275 ribodepletion. Briefly, RNA sequencing was performed using the Illumina Stranded with
276 RiboZero library preparation method. Sample quality and integrity were assessed using
277 TapeStation RNA analysis. Sequencing was conducted on the Illumina NextSeq platform,
278 followed by standard bioinformatics analysis for gene expression quantification.

279 The service was provided by the Biomedicum Functional Genomics Unit at the Helsinki
280 Institute of Life Science and Biocenter Finland at the University of Helsinki.

281

282 **RT-qPCR of mouse samples**

283 RNA was extracted from dissected lung samples (1/10 of the whole lung) of mice in Exp 1 and
284 Exp 3 as well as isolated neutrophils using Trizol (Thermo Scientific) following the

285 manufacturers' instructions. The isolated RNA was directly subjected to one-step RT-qPCR
286 analysis based on a previously described protocol using primer-probe sets detecting the viral
287 genome encoding for the RNA-dependent RNA polymerase (RdRp) (26), subgenomic E (27)
288 as well as mouse caspase1, IL1b and GAPDH (Applied biosystems #Mm00438023_m1,
289 #Mm00434228_m1 and #Mm99999915_g1 respectively, Thermo scientific). The PCRs were
290 performed with TaqPath 1-step master mix (ThermoFisher Scientific) using AriaMx
291 instrumentation (Agilent, Santa Clara, CA, USA).

292

293 **Histology and immunohistochemistry**

294 From animals in Exp 1 and Exp 3 the whole left lung (Exp 1) or 1/5 of the left lung (Exp 3)
295 were trimmed for histological examination and routinely paraffin wax embedded. Consecutive
296 sections (3 µm) were prepared and routinely stained with hematoxylin-eosin (HE) or subjected
297 to immunohistochemistry (IHC) for the detection of SARS-CoV-2 nucleoprotein (NP) (28) and
298 Ly6G (neutrophil marker); for Exp 3, a further section of the infected lungs was stained for
299 histone H3 (NET marker) (29). All stains followed previously published protocols (30).

300

301 **Morphometric analyses**

302 For quantification of SARS-CoV-2 antigen expression and the extent of neutrophil influx into
303 the lungs, a morphometric analysis was undertaken on the slides stained for SARS-CoV-2 NP
304 and Ly6G, respectively. The stained slides were scanned using NanoZoomer 2.0-HT
305 (Hamamatsu, Hamamatsu City, Japan), and several sections of the lung of each animal were
306 quantitatively analysed using the Visiopharm 2022.01.3.12053 software (Visiopharm,
307 Hoersholm, Denmark). The average total tissue area used for quantification was $19.5 \pm 6 \text{ mm}^2$.
308 The morphometric analysis served to quantify the area, in all lung sections of an animal, that
309 showed immunostaining for viral NP and Ly6G, respectively. In Visiopharm, for each section,

310 the lung was manually outlined and annotated as a Region Of Interest (ROI), manually
311 excluding artifactually altered areas. The manual tissue selection was further refined with an
312 Analysis Protocol Package (APP) based on a Decision Forest classifier, with the pixels from
313 the ROI being ultimately classified as either “Tissue” or “Background”. This new “Tissue”
314 ROI, regrouping the different lung samples analysed for each animal, was further quantified
315 by executing two APPs successively. The first APP was based on a Threshold classifier and
316 served to detect and outline areas with immunostaining. The second APP then measured both
317 the surface of the immunostained area (μm^2) and the surface of the “Tissue” ROI (μm^2). The
318 percentage of immunostained area (%), expressed as the ratio between the immunostained area
319 and the total area, was obtained for each animal in Excel (Microsoft Office 2019; Microsoft,
320 Redmond, Washington, United States), according to the following formula: ([positive area
321 (μm^2)] / [total area (μm^2)]) x 100.

322

323 **Statistical analyses**

324 Statistical analysis was performed using GraphPad Prism 8.3 software (GraphPad Software,
325 San Diego, CA, USA) and R software v3.6.3 (R core team). Statistically significant correlations
326 between parameters were assessed by calculating Spearman’s correlation coefficients, and
327 differences between groups were assessed with Mann-Whitney, Kruskal-Wallis or ordinary
328 one-way or 2-way ANOVA tests, depending on sample distribution and the number of groups
329 analyzed. To elaborate, nonparametric tests like Mann-Whitney and Kruskal-Wallis were
330 employed when the data violated assumptions of normality, while ANOVA tests were applied
331 when the data met parametric assumptions.

332 **Results**

333 **Unsupervised RNA-seq analysis reveals an antiviral gene expression signature of** 334 **circulating neutrophils in COVID-19 that is strongly influenced by maturity**

335

336 With our recent findings on increased frequencies of low-density granulocytes (LDGs, isolated
337 from the PBMC fraction) during COVID-19 and their likely relevant role in disease progression
338 (7), we sought to understand in more detail how the transcriptomic profile of LDGs differs
339 from their higher “normal” density counterpart, the circulating polymorphonuclear cells
340 (PMNs) (31), typically consisting mainly of mature neutrophils. Neutrophils isolated from
341 different cohorts comprised three PMN groups (severe COVID-19, mild COVID-19, and
342 healthy controls), and one LDG group. Initial deconvolution of the RNA sequencing (RNA-
343 seq) data allowed us to gain a comprehensive understanding of the cellular composition within
344 PMN and LDG fractions and verified that most cells present in the samples were neutrophils
345 (Supplementary Figure 1A). This analysis also demonstrated that cells in the LDG fraction
346 were predominantly immature neutrophils, meanwhile PMNs were composed of mainly mature
347 neutrophils.

348 The samples with predominant neutrophil cell populations were selected for subsequent gene
349 expression analysis (neutrophils $\geq 65\%$). The high variance in gene expression between PMNs
350 and LDGs was confirmed by principal component analysis (PCA) (Figure 1A), which revealed
351 that the gene expression patterns of COVID-19 LDGs differed from those of all PMNs
352 regardless of the patients’ disease state. Functional enrichment analyses through gene
353 overrepresentation (ORA) and gene-set enrichment analyses (GSEA) (Figure 1B) compared
354 PMNs with LDGs from severe COVID-19 patients. The most statistically significant result was
355 an overrepresentation of the NOD-like receptor signaling pathway in PMNs in contrast with
356 LDGs, highlighting that the different neutrophil fractions have a distinct inflammatory profile.

357 This was supported by GSEA, where the most obvious increases in fold changes were the
358 enrichment of the interferon signaling pathways. Another relevant difference was the cell cycle
359 and DNA replication pathways, identified by both ORA and GSEA, which supported our
360 previous findings suggesting LDGs to be predominantly immature cells (7). Furthermore, a
361 heatmap of selected type I IFN (IFN-I) related genes confirmed a robust IFN-I gene signature
362 in severe COVID-19 PMNs, while LDGs from severe COVID-19 distinctively lacked this
363 signature (Figure 1C). Unsupervised clustering analysis, namely Iterative Clustering and Guide
364 Gene Selection (ICGS) using the AltAnalyze software, supported these findings by identifying
365 the top 118 differentially expressed (DE) genes, including several IFN-related genes
366 (Supplementary Fig. 1B). Similarly to the selected samples included in Figure 1, this analysis
367 classified the samples into two major clusters: a first one containing all isolated LDG samples,
368 and a second one comprising all isolated PMN samples. The former cluster consisted of
369 neutrophil antimicrobial and granule marker genes (e.g. *DEFA3*, *DEFA4*, *SERPINB10*, *CTSG*),
370 while in the latter cluster the most significantly upregulated genes in the PMNs from severe
371 COVID-19 subgroup were mainly interferon inducible (e.g. *IFI44L*, *IFI6*, *GBP3*, *IRF7*). These
372 differences were supported by a detailed gene analysis (Supplementary Fig. 2A).

373 **Inflammasomes are activated in severe COVID-19 PMNs, but not directly by SARS-CoV-** 374 **2**

375 Looking more closely into PMN fractions, pathway analyses identified the inflammasome
376 related NOD-like and RIG-like receptor signaling pathways among the most significantly
377 overrepresented pathways, differentially expressed in severe COVID-19 PMNs versus HC
378 PMNs (Figure 2A and Supplementary Fig. 2B-C) or mild COVID-19 PMNs (Figure 2B and
379 Supplementary Fig. 2D, E). However, mild COVID-19 PMNs did not significantly differ from
380 HC PMNs in their inflammatory profile (Supplementary Fig. 2F). The increased expression of

381 selected IFN-I (*OAS1*, *OAS2*, and *IFIT1*) and inflammasome related genes (*CASP1*, *CASP5*,
382 *NLRC5* and *NAIP*) was confirmed by RT-qPCR. However, some inflammasome related genes
383 (*IL-1 β* , *NLRP3* and *NLRC4*) were seemingly downregulated, although not statistically
384 significant (Supplementary Fig. 3).

385 Given the strong upregulation of many inflammasome related genes during severe COVID-19,
386 we assessed whether PMNs exhibit active inflammasome formation *in vivo*. To evaluate
387 spontaneous inflammasome mediated cytokine secretion, fresh PMNs isolated from severe
388 COVID-19 patients and HC were cultured *ex vivo* overnight. We measured the levels of IL-1 β
389 and IL-18 in the supernatant and found that IL-1 β secretion was significantly increased in the
390 supernatant of severe COVID-19 PMNs compared to HC PMNs (Figure 2C), whereas the IL-
391 18 levels did not differ significantly (Figure 2D). Additionally, since SARS-CoV-2 viral
392 particles were previously implicated to induce inflammasome formation in macrophages (17),
393 the IL-1 β and IL-18 levels after HC PMNs exposure to SARS-CoV-2 were also assessed but
394 no significant effects in the secretion of these cytokines were observed (Figure 2E, F).

395 The spontaneous secretion of IL-1 β by COVID-19 PMNs suggests that these cells are actively
396 producing and releasing IL-1 β through inflammasome formation which is dependent on
397 caspase1 activity (32). We assessed caspase1 activity in response to the second signal required
398 for inflammasome activation, induced by nigericin, and observed increased caspase1 activity
399 in severe COVID-19 PMNs compared to HC PMNs (Figure 2G). These findings suggest that
400 severe COVID-19 PMNs have an increased capacity for inflammasome activation, potentially
401 due to an existing priming signal during acute disease *in vivo*. However, no significant
402 difference in caspase1 activity between non-exposed and virus-exposed PMNs were observed
403 (Figure 2G), indicating that caspase1 activation in COVID-19 PMNs is not directly triggered
404 by the virus.

405 **Activation of neutrophil inflammasome related pathways during respiratory distress is**
406 **not specific to COVID-19**

407 We also reanalyzed the RNA-seq data generated by LaSalle *et al.* (8), focusing on neutrophil
408 transcriptomics in patients with COVID-19 as compared to non-COVID-19 patients, and
409 healthy controls. The non-COVID-19 patients were presented with acute respiratory distress
410 and clinical concern for COVID-19 but tested negative for SARS-CoV-2 by PCR. Our analysis
411 included IFN- α response, IL-1 β production, TLR signaling, NLRP3 inflammasome, and
412 pyroptosis pathways, using the Gene Ontology (GO) database; the NLR signaling pathway
413 using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database; and inflammasome
414 pathway using the REACTOME database (Figure 3). These pathways were significantly
415 enriched in COVID-19 patients, supporting our findings. Importantly, the genes from the
416 above-mentioned pathways were also induced in non-COVID-19 patients, suggesting that
417 these pathways represent a general neutrophil response to inflammatory stimuli rather than a
418 COVID-19 specific response.

419

420 **Type I IFNs prime PMNs for inflammasome activation**

421 Since PMNs from COVID-19 patients concomitantly display a strong IFN-I signature (Figure
422 1B-C) and an increased propensity for inflammasome activation, we hypothesized that IFN-I
423 could act as the priming signal for PMN inflammasomes during COVID-19. Isolated HC PMNs
424 were stimulated *ex vivo* with exogenous IFN-I and the well-described inflammasome priming
425 (1st signal) and activator (2nd signal) agents LPS and nigericin, respectively (33, 34). After
426 stimulation, both priming signals induced pro-IL-1 β (31 kDa) in the cell lysates, followed by
427 the release of active IL-1 β (17 kDa) into the supernatant in response to nigericin (Figure 4A),
428 confirming the ability of IFN-I to prime PMNs for inflammasome activation.

429 To assess inflammasome formation in circulating neutrophils during COVID-19, PMNs from
430 HC and COVID-19 patients underwent similar stimulation assays as above, followed by IL-1 β
431 measurement from supernatants by ELISA. In addition, to further assess the role of SARS-
432 CoV-2 virus particles in neutrophil inflammasome activation, HC PMNs were cultured in the
433 presence of purified viruses (10 infectious units/PMN). HC PMNs responded to both LPS and
434 IFN-I by increasing their IL-1 β secretion, which was exponentiated after exposure to nigericin
435 (Figure 4A-B), confirming the ability of IFN-Is to prime for inflammasome assembly in PMNs,
436 albeit less efficiently than LPS. Interestingly, COVID-19 PMNs produced less IL-1 β than HC
437 PMNs upon exogenous inflammasome activation primed by either LPS or IFN-I, while SARS-
438 CoV-2 particles did not have any effect on PMN inflammasome activation (Figure 4B). As
439 with 24-h cultures (Figure 2D), we did not detect any significant changes in IL-18 secretion in
440 either HC or COVID-19 PMNs (Supplementary Fig. 4A). However, the release of
441 myeloperoxidase (MPO), used as a marker of degranulation and/or NETosis, in response to
442 nigericin was similar between COVID-19 PMNs and HC PMNs, and therefore the observed
443 diminished IL-1 β release by COVID-19 PMNs is not due to general cellular inertia but may be
444 specific to the *ex vivo* induced inflammasome pathway. Furthermore, additional stimulation
445 assays in the presence of the NLRP3 inhibitor MCC950 (Figures 4D-E) and caspase1 inhibitor
446 YVAD (Supplementary Fig. 4B) confirmed that induced IL-1 β secretion is dependent on
447 canonical NLRP3 inflammasome activation. Unlike IL-1 β (Supplementary Fig. 4C), increased
448 IL-18 secretion was not detectable even after 24-h stimulation (Supplementary Fig. 4D).
449 Furthermore, the observed residual IL-18 was not affected by inflammasome inhibitors,
450 suggesting its secretion to be unrelated to inflammasome activity in PMNs.

451 We further assessed the specificity of inflammasome activation by measuring LDH and IL-8
452 levels in the supernatants from the same cells and under the same experimental conditions as
453 shown in Figures 4D-E. The measurements of the former were done to assess inflammasome

454 mediated cell death by pyroptosis in response to nigericin, while the latter was assessed to
455 demonstrate the responsiveness of PMNs to an inflammasome unrelated inflammatory cascade.
456 As with IL-1 β secretion, COVID-19 PMNs were less responsive than HC PMNs to nigericin-
457 and LPS-mediated LDH (Figure 4F) and IL-8 (Figure 4G) release, respectively. This suggests
458 that COVID-19 PMNs are generally poorly responsive to inflammatory stimuli.

459 To examine this reduced responsiveness to external inflammatory priming, we evaluated the
460 inflammasome related gene expression following *ex vivo* stimulation with IFN-I or LPS (Figure
461 4H-K and Supplementary Fig. 4E-H). OAS1 gene, an interferon stimulated gene (ISG), showed
462 significant upregulation by IFN-I in COVID-19 PMNs as compared to HC PMNs (Figure 4H),
463 while the inflammasome related genes IL-1 β (Figure 4I), CASP1 (Figure 4J) and NLRC5
464 (Figure 4K) were more efficiently induced in HC PMNs than COVID-19 PMNs. This suggests
465 that the inflammasome defect in COVID-19 PMNs is at the transcriptional level when using
466 IFN-I as the priming factor, while high OAS1 gene expression indicates transcriptional defect
467 is restricted to individual genes.

468 **Association between *ex vivo* inflammasome activation and disease severity**

469 Our analysis of the association between *ex vivo* inflammasome activation (caspase1 activity
470 and IL-1 β release) and clinical markers of disease severity, including neutrophil responses,
471 revealed intriguing links. Calprotectin is a marker of neutrophil activation or death (35) but
472 also potentially activates the inflammasome (36). A significant positive correlation between
473 calprotectin plasma levels and PMN caspase1 activity (Figure 5A-B) underscores this latter
474 possibility and highlights the interplay between inflammation and inflammasome activation in
475 PMNs of COVID-19 patients. Furthermore, the negative association of PMN IL-1 β levels (after
476 *ex vivo* stimulation with IFN and nigericin) with disease severity (WHO ordinal scale, Figure
477 5A) and patient neutrophil counts (Figure 5A, C) supports the exhaustion hypothesis, wherein

478 PMNs from severe COVID-19 patients may be less responsive to stimuli due to prior *in vivo*
479 activation. While these findings provide intriguing insights into the complex interplay between
480 calprotectin release, caspase1 activity, and inflammasome activation in COVID-19, additional
481 research is required to further elucidate these connections.

482 **LDGs differ from PMNs in gene expression and release of inflammasome related**
483 **interleukins**

484 To assess the inflammasome related inflammatory profile of COVID-19 LDGs in comparison
485 to PMNs, we analyzed the differential expression of inflammasome related genes using RNA-
486 seq (Figure 6A). LDGs differed significantly from PMNs, with the most striking difference
487 being their increased expression of IL-18 and NLRC4, whereas PMNs displayed higher levels
488 of IL-1 β , NLRP3 and caspases 1, 4 and 5. Single cell sequencing data from the COVID-19
489 immune atlas confirmed our transcriptomic results (Figure 6B), from which a detailed gene by
490 gene analysis of the most relevant inflammasome related genes is shown (Figure 6C and
491 Supplementary Fig. 5). Briefly, PYCARD gene coding for the ASC protein was expressed
492 similarly in mature and immature neutrophils (Supplementary Fig. 5), confirming that both cell
493 types have inflammasome forming capacity. However, most of the inflammasome gene
494 expressions differed significantly and in the same manner as in our transcriptomic analysis.

495

496 We conducted *ex vivo* stimulation assays using LDGs isolated from COVID-19 patients,
497 similar to the approach used for PMNs described earlier. Like PMNs, IL-1 β secretion by LDGs
498 was elevated in the presence of a priming signal (IFN-I or LPS), which exponentially increased
499 when the inflammasome activation signaling molecule nigericin was added (Figure 6D).
500 Contrary to PMNs and in line with the transcriptomics data, an increased IL-18 secretion was

501 detected (Figure 6E). Additionally, the secretion of both ILs by LDGs was inhibited in the
502 presence of inflammasome specific inhibitors MCC950 and YVAD (Figure 6F-G).
503 These findings suggested that the outcome of neutrophil inflammasome activation varies based
504 on cellular maturation state. To explore this further, we conducted *in vitro* stimulation studies
505 using differentiated HL-60 cells, an immature neutrophil-like model (37). Similar to LDGs
506 from COVID-19 patients, HL-60 displayed comparable IL-18 secretion pattern upon LPS or
507 IFN-I stimulation and nigericin-induced activation. Notably, their IL-1 β release was only
508 detected with LPS priming (Figures 6F-G). Furthermore, consistent with transcriptomic
509 analysis revealing an upregulation of inflammasome related genes upon differentiation (Figure
510 6H), the capacity of HL-60 cells to secrete inflammasome related cytokines was differentiation-
511 dependent (data not shown). Overall, these findings suggest that neutrophils may lose the
512 ability to secrete IL-18 during maturation, and release of neutrophil-derived IL-18 occurs
513 primarily in disease states associated with extensive granulopoiesis and increased immature
514 granulocyte counts in the blood, like COVID-19 (38).

515

516 **Neutrophils are recruited to the lungs in SARS-CoV-2 infected mice**

517 Hamsters and human ACE2 expressing mice infected with SARS-CoV-2 develop pulmonary
518 inflammation including neutrophil recruitment (39–41). To further assess the role of
519 neutrophils in COVID-19, we utilized a recently developed SARS-CoV-2 mouse model (18).
520 This model employs the MaVie strain, serially passaged in mouse lungs and causing
521 pneumonia similar to human COVID-19 in wild-type BALB-C mice (18). Infected mice started
522 losing weight by day 2 post-infection, with some mice reaching the clinical endpoint of 20%
523 weight loss by day 4 (Supplementary Fig. 7A, includes animals from 3 independent infection
524 experiments, details of animal usage in Table S2). The first experiment (Exp1) was performed
525 to study infection kinetics and Ly-6G⁺ neutrophil accumulation in lungs. Viral loads were

526 significantly higher at 2 dpi than 4 dpi (Supplementary Fig. 6A), and viral antigen expression,
527 widespread at 2dpi in bronchioles and alveoli, matched this pattern (Supplementary Fig. 6B
528 and D).The extensive viral replication at 2 dpi was associated with degeneration of infected
529 epithelial cells, most prominent in the respiratory epithelium, accompanied by neutrophil
530 (Ly6G+) infiltration (Supplementary Fig. 6D) and a significant increase in the number of
531 neutrophils in the lungs of infected mice compared to PBS-inoculated mice (Supplementary
532 Fig. 6C). Neutrophil numbers significantly decreased by 4dpi but remained higher than controls
533 (Supplementary Fig. 6C). Detailed information on the histological and immunohistochemical
534 features of these mice is provided in Supplementary Table S2. Together, these findings suggest
535 a pivotal role of neutrophils in clearing the virus in SARS-CoV-2 infected mice.

536

537 **Neutrophils from SARS-CoV-2 infected mice display IFN-I dependent caspase1** 538 **activation**

539 In the second infection experiment (Exp2) we isolated neutrophils from the lungs of infected
540 mice at 2 and 4 dpi, as well as from non-infected mice (inoculated with PBS) for transcriptomic
541 analysis by RNA-seq. PCA showed differences between neutrophils from infected and non-
542 infected mice, with slight variation between the 2 and 4 dpi time points (Figure 7A). These
543 differences were reflected in many DEGs, including several IFN-I responsive and
544 inflammasome related genes, which showed strong upregulation at 2 dpi with slightly lower
545 but still significantly elevated levels at 4 dpi, compared to non-infected mice (highlighted in
546 the DEG heatmap; Figure 7B). The volcano plot (Figure 7C) provided a comprehensive view
547 of the DEG pattern between neutrophils from SARS-CoV-2 infected and mock-infected mice.
548 In addition to confirming the upregulation of IFN-I responsive and inflammasome related
549 genes observed in the heatmap, the plot revealed a broader transcriptional response to viral
550 infection with several additional DEG.

551 We also investigated if neutrophils from SARS-CoV-2 infected mice showed increased
552 inflammasome formation, like PMNs from COVID-19 patients. Neutrophils from infected
553 mice, harvested at 2 and 4 dpi, displayed increased caspase1 activity upon nigericin
554 stimulation, compared to neutrophils from non-infected mice (Exp 2; Figure 7D). The third
555 infection experiment (Exp3) was performed to assess the role of IFN-I by inoculating mice
556 with an IFN-I blocking anti-IFNAR monoclonal antibody or an isotype control antibody post-
557 infection. Remarkably, neutrophils from anti-IFNAR treated mice showed diminished
558 nigericin-induced caspase1 activity (Figure 7E). Furthermore, caspase1 and IL-1 β gene
559 expressions were lower in anti-IFNAR treated than isotype treated mice (Figure 7F-G). Taken
560 together, IFN-I appears to be responsible for the increased caspase1 activity in neutrophils of
561 infected mice.

562 The histology of isotype-treated mice and anti-IFNAR treated mice lungs showed comparable
563 features (Supplementary Fig. 7C) as infections without antibody (Exp 1; Supplementary Fig.
564 7B-D). Regardless of treatment, some neutrophils in infected mice displayed degeneration and
565 NETosis evidenced by histone H3cit staining (Supplementary Fig. 7C; Supplementary Table
566 S2), and viral loads remained consistent between anti-IFNAR or IgG1 isotype control treated
567 mice (Supplementary Fig. 7B). Taken together, blocking IFN-I signaling did not alter virus
568 replication, virus-induced pathological changes, or early neutrophil recruitment following
569 infection.

570 **Discussion**

571 Neutrophils, the largest cell population of the host immune system, are rapidly recruited to sites
572 of infection and play an important role in orchestrating an early immune response (42, 43). The
573 relevance of neutrophils in viral infections became increasingly apparent during the COVID-
574 19 pandemic, as they have been shown to be key mediators of the observed pathological
575 processes (44).

576 This study sheds light on the potential involvement of the inflammasome pathway in COVID-
577 19, particularly by demonstrating its activation in neutrophils during SARS-CoV-2 infection.
578 Our investigation of the inflammatory profile of neutrophils as the dominant population of
579 peripheral blood polymorphonuclear cells (PMNs) revealed an increased ability of neutrophils
580 from severe COVID-19 patients for inflammasome assembly as evidenced by their
581 transcriptional profile, spontaneous release of IL-1 β , and elevated caspase1 activity. These
582 findings are consistent with previous reports indicating activation of the NLRP3 inflammasome
583 and ASC specks in circulating neutrophils during acute COVID-19 (14, 16). Furthermore,
584 despite showing increased caspase1 activity, neutrophils from COVID-19 patients exhibited
585 diminished soluble IL-1 β production upon exogenous activation of the NLRP3 inflammasome
586 pathway compared to healthy controls, which suggests that this pathway is “exhausted” due to
587 prior activation during the disease. Mechanistically, our findings show that IFN-I, elevated in
588 COVID-19 patients (45, 46), can prime inflammasome formation in neutrophils.
589 Transcriptomic analyses revealed that circulating neutrophils during severe COVID-19 show
590 increased expression of IFN-responsive genes, suggesting inflammasome priming by IFN-I
591 also *in vivo* during COVID-19 (47). Furthermore, the study found that immature neutrophils,
592 which are prevalent in low-density granulocyte fraction (LDGs), exhibit unique inflammasome
593 gene expression and outcomes compared to mature neutrophils (PMNs). LDGs release IL-18

594 and upregulate distinct inflammasome related genes but lack the IFN-I signature seen in PMNs
595 during COVID-19, indicating lower responsiveness to IFN-I, and supported by less efficient
596 IFN-I mediated inflammasome priming of LDGs *ex vivo*.

597 SARS-CoV-2 infected mice also showed increased neutrophil caspase1 activity, reversible by
598 an IFN-I receptor (IFNAR) blocking antibody. Transcriptional analysis revealed a robust IFN-
599 I signature and elevated expression of inflammasome genes encoding for caspase1 and IL-1 β
600 in neutrophils of infected mice, which were also inhibited by blocking IFNAR signaling,
601 suggesting that IFN-I may also prime for inflammasome activation in mice. Notably, the anti-
602 IFNAR treatment did not affect neutrophil recruitment or NETosis, which is consistent with
603 another COVID-19 model using transgenic human ACE2, where IFNAR knockout inhibited
604 recruitment of monocytes and lymphocytes, but not neutrophils, to infected lungs (48).

605 Inflammasomes were first studied in macrophages, revealing many molecular mechanisms
606 regulating inflammasome assembly (49). Macrophage inflammasome activation has emerged
607 as a major factor also in COVID-19 (17). Interestingly, macrophage inflammasome activation
608 was recognized to be IFN-I mediated in an experimental rhesus macaque COVID-19 model
609 (50). However, due to the abundance of neutrophils compared with cells of
610 monocyte/macrophage lineage (51, 52), the significance of neutrophil inflammasomes in
611 COVID-19 is likely underestimated. Our results highlight inflammasomes as an additional
612 important inflammatory mechanism in neutrophils (14), complementing their role in
613 phagocytosis, reactive oxygen species generation, degranulation, and NETosis (31).

614 SARS-CoV-2 can directly activate inflammasomes in cells of the monocyte/macrophage
615 lineage (17). Our study investigated whether SARS-CoV-2 can provide the first or second
616 signal for inflammasome activation in neutrophils. However, we found no evidence of direct
617 virus-induced inflammasome activation in neutrophils. The difference between macrophages

618 and neutrophils in their susceptibility to SARS-CoV-2 could depend on many factors. Both cell
619 types express ACE2, the receptor for SARS-CoV-2, but may differ in ACE2 expression levels
620 (53). Furthermore, the intracellular environment of macrophages is better suited for viral
621 replication (54), while neutrophils focus on phagocytosis and antimicrobial responses (31, 55).
622 Additionally, pathogen opsonization can trigger inflammasomes in macrophages (56) but is
623 not a primary function of neutrophils. Therefore, our findings suggest neutrophil
624 inflammasome activation in response to SARS-CoV-2 likely results from interactions with
625 infected and/or dying cells in the lungs, rather than direct virus activation. To note, whether
626 SARS-CoV-2 can induce neutrophil inflammasomes through immune complex-mediated
627 mechanisms, as seen in monocytes/macrophages (17) remains to be determined.

628 In this study, we demonstrated IFN-I as the first signal for NLRP3 inflammasome activation in
629 neutrophils. While prior research has explored IFN-inflammasome crosstalk (57), priming
630 capacity of IFN-I remained unclear. While IFN-I promotes inflammasomes in epithelial cells
631 (58) it can also dampen IL-1 β in macrophages (59). Plausibly, initial IFN-I exposure may
632 upregulate inflammasome genes, whereas prolonged activity could hinder IFN-I signaling via
633 “negative feedback” loop, in line with our findings of inflammasome exhaustion in circulating
634 neutrophils of severe COVID-19 patients. It should be noted that several SARS-CoV-2
635 encoded proteins have been shown to inhibit IFN-I signaling (60). However, no evidence
636 suggests that neutrophils can be infected by SARS-CoV-2 and therefore it seems unlikely that
637 such direct virus mediated effects could play a role in the observed neutrophil unresponsiveness
638 to IFN-I.

639 The dualistic nature of the IFN-I response in COVID-19 has been recognized previously. It
640 seems that a strong initial IFN-I response to SARS-CoV-2 is more likely to result in
641 asymptomatic or mild COVID-19 whereas a decreased initial IFN-I activity, due to e.g. genetic
642 defects or increased levels of IFN-I autoantibodies, can lead to more severe COVID-19 (61).

643 This initial beneficial effect of IFN-I is probably due to its ability to limit viral replication at
644 early stages of the infection. However, at later stages of the disease IFN-I can be detrimental
645 by promoting inflammatory pathways instead of direct antiviral effects (62). Thus, similarly to
646 the IFN-I response in general, the role of neutrophil inflammasomes in development and
647 severity of COVID-19 might be dualistic in nature with an initial protective effect while
648 damaging when sustained for prolonged periods.

649 Our study demonstrated a strong association between PMN caspase1 activity and plasma levels
650 of calprotectin, a marker of neutrophil activation. Additionally, increased disease severity, as
651 assessed by the WHO ordinal scale, was significantly linked to PMNs being less responsive to
652 *ex vivo* IFN-induced inflammasome activation. Thus, these results suggest that neutrophil
653 inflammasomes playing a potential role in disease severity rather than being protective in
654 COVID-19.

655 Our study also unveiled distinct gene profiles in LDGs and PMNs from severe COVID-19
656 patients. LDGs exhibited upregulation of genes related to DNA replication and cell cycle,
657 indicating immaturity, and confirming our prior findings (7). Conversely, PMNs displayed
658 heightened NLR signaling, suggesting a robust response to pathogens. While our study
659 compared PMNs and LDGs, and the COVID-19 Immune Atlas single cell analysis represented
660 a broader classification of mature and immature neutrophils, the alignment of our results with
661 the atlas provides further support for the distinct characteristics of these two neutrophil
662 populations in severe COVID-19. Notably, IL-18 gene expression and secretion after *ex vivo*
663 stimulation were higher in LDGs than PMNs. To note, PMN's lack of IL-18 secretion is not
664 due to lack of protein, as they constitutively express significant amounts intracellularly (63).
665 This indicates a similarity between LDGs and monocytes/macrophages in inflammasome
666 mediated IL-18 processing, possibly lost during neutrophil maturation.

667 The present study has some limitations worth discussing. Firstly, the relatively small human
668 sample size may limit the generalizability of the findings. While RNA-seq provided valuable
669 insights into gene expression profiles of PMNs and LDGs, we did not perform functional
670 validation of the identified pathways in this study. Regarding our experimental SARS-CoV-2
671 disease model, the high virus input might trigger robust immune responses that differ from
672 typical human infections, and the short-lived virus replication in the applied model does not
673 capture the effect of prolonged antigen exposure or the complex inflammatory milieu seen in
674 human cases. Furthermore, the observed inhibitory effects on neutrophil inflammasome
675 activity by IFNAR blockade does not exclude the possibility that IFN-I could promote
676 neutrophil inflammasome formation by indirect effects such as stimulating the release of pro-
677 inflammatory cytokines by other cell types. Finally, since the prominent role of neutrophils in
678 the immune response to viral infections is widely recognized (42, 43) and it would be valuable
679 to compare these findings to neutrophil responses in other viral respiratory infections.

680

681 Taken together, our findings provide valuable insights into neutrophil involvement in COVID-
682 19 and possibly other viral respiratory infections. However, further research is needed to fully
683 grasp the role of neutrophil inflammasomes in COVID-19 pathogenesis. This increased
684 understanding may facilitate the development of targeted treatment approaches for COVID-19.
685 For example, pharmacologically targeting the inflammasome pathway in neutrophils with
686 novel inhibiting molecules (64), may help mitigate the exaggerated inflammatory response
687 observed in severe cases. The next steps involve validating the pathways and genes identified
688 as potential therapeutic targets and assessing their COVID-19 specificity. Prospectively, these
689 strategies could be extended to address upcoming respiratory virus pandemics, where
690 neutrophils and inflammasomes provide major pathogenic contributions.

691 **Contributors**

692 L.E.C.: conceptualization, data curation, formal analysis, investigation, software, validation,
693 visualization, writing– original draft; S.T.J.: investigation, writing – review & editing; Sa.M.:
694 investigation; Si.M.: investigation; R.K.: resources; L.K.; investigation, writing – review &
695 editing; Ta.S.: resources; J-P.P.: resources; Anu.K.: funding acquisition, resources, writing –
696 review & editing; E.K.: supervision, writing – review & editing; H.L.: resources; P.M.:
697 resources, writing – review & editing; Anj.K.: investigation, methodology, supervision,
698 validation, visualization, writing – review & editing; O.V.: funding acquisition, resources;
699 To.S.: conceptualization, data curation, formal analysis, funding acquisition, investigation,
700 methodology, project administration, supervision, validation, writing – original draft.

701

702 **Declaration of Competing Interest**

703 All authors declare no financial competing interests related to the study.

704

705 **Acknowledgements**

706 This work was financed by grants by the Academy of Finland to To.S. (321809), Anu.K.
707 (336439 and 335527); grants by the Helsinki University Hospital funds to O.V. (TYH
708 2021343); EU Horizon 2020 programme VEO (874735) to O.V.; Finnish governmental
709 subsidy for Health Science Research (TYH 2021315) to Anu.K.; Paulon Säätiö to L.E.C.;
710 Suomen Lääketieteen Säätiö to L.E.C.; Jane and Aatos Erkko foundation to O.V. The funders
711 had no role in study design, data collection and analysis, nor decision to publish, or preparation
712 of the manuscript.

713 RNA isolation, library preparations and RNA sequencing was performed at the Institute for
714 Molecular Medicine Finland FIMM, Genomics unit supported by HiLIFE and Biocenter
715 Finland. The authors also thank M. Utriainen for expert technical assistance.

716

References

- 717 1. Wilk AJ, et al. Multi-omic profiling reveals widespread dysregulation of innate
718 immunity and hematopoiesis in COVID-19. *Journal of Experimental Medicine*.
719 2021;218(8). <https://doi.org/10.1084/jem.20210582>.
720 2. Blanco-Melo D, et al. Imbalanced Host Response to SARS-CoV-2 Drives
721 Development of COVID-19. *Cell*. 2020;181(5):1036-1045.e9.
722 3. Hadjadj J, et al. Impaired type I interferon activity and inflammatory responses in
723 severe COVID-19 patients. *Science (1979)*. 2020;369(6504):718–724.
724 4. Domizio J Di, et al. The cGAS–STING pathway drives type I IFN
725 immunopathology in COVID-19. *Nature*. 2022;603(7899):145–151.
726 5. Barnes BJ, et al. Targeting potential drivers of COVID-19: Neutrophil extracellular
727 traps [preprint]. *Journal of Experimental Medicine*. 2020;217(6).
728 <https://doi.org/10.1084/jem.20200652>.
729 6. Radermecker C, et al. Neutrophil extracellular traps infiltrate the lung airway,
730 interstitial, and vascular compartments in severe COVID-19. *Journal of Experimental*
731 *Medicine*. 2020;217(12). <https://doi.org/10.1084/jem.20201012>.
732 7. Cabrera LE, et al. Characterization of low-density granulocytes in COVID-19. *PLoS*
733 *Pathog*. 2021;17(7). <https://doi.org/10.1371/journal.ppat.1009721>.
734 8. LaSalle TJ, et al. Longitudinal characterization of circulating neutrophils uncovers
735 phenotypes associated with severity in hospitalized COVID-19 patients. *Cell Rep Med*.
736 2022;3(10). <https://doi.org/10.1016/j.xcrm.2022.100779>.
737 9. Schulte-Schrepping J, et al. Severe COVID-19 Is Marked by a Dysregulated
738 Myeloid Cell Compartment. *Cell*. 2020;182(6):1419-1440.e23.
739 10. Ueda Y, Kondo M, Kelsoe G. Inflammation and the reciprocal production of
740 granulocytes and lymphocytes in bone marrow. *Journal of Experimental Medicine*.
741 2005;201(11):1771–1780.
742 11. Zuo Y, et al. Neutrophil extracellular traps in COVID-19. *JCI Insight*. 2020;5(11).
743 <https://doi.org/10.1172/jci.insight.138999>.
744 12. Potere N, et al. Interleukin-1 and the NLRP3 inflammasome in COVID-19:
745 Pathogenetic and therapeutic implications. [published online ahead of print: 2022].
746 <https://doi.org/10.1016/j>.
747 13. Lechtenberg BC, Mace PD, Riedl SJ. Structural mechanisms in NLR
748 inflammasome signaling [preprint]. *Curr Opin Struct Biol*. 2014;29:17–25.
749 14. Aymonnier K, et al. Inflammasome activation in neutrophils of patients with
750 severe COVID-19. *Blood Adv*. 2022;6(7):2001–2013.
751 15. Courjon J, et al. Heterogeneous NLRP3 inflammasome signature in circulating
752 myeloid cells as a biomarker of COVID-19 severity. *Blood Adv*. 2021;5(5):1523–1534.
753 16. Leal VNC, et al. Severe COVID-19 patients show a dysregulation of the NLRP3
754 inflammasome in circulating neutrophils. *Scand J Immunol*. [published online ahead of
755 print: 2022]. <https://doi.org/10.1111/sji.13247>.
756 17. Sefik E, et al. Inflammasome activation in infected macrophages drives COVID-19
757 pathology. *Nature*. 2022;606(7914):585–593.
758 18. Gawish R, et al. ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel
759 COVID-19 mouse model with TNF- and IFN γ -driven immunopathology. *Elife*.
760 2022;11. <https://doi.org/10.7554/eLife.74623>.
761 19. Rusanen J, et al. A Generic, Scalable, and Rapid Time-Resolved Förster
762 Resonance Energy Transfer-Based Assay for Antigen Detection-SARS-CoV-2 as a
763 Proof of Concept. [published online ahead of print: 2021].
764 <https://doi.org/10.1128/mBio>.


- 765 20. Liu P, et al. ExpressAnalyst: A unified platform for RNA-sequencing analysis in
766 non-model species. *Nat Commun.* 2023;14(1):2995.
- 767 21. Emig D, et al. AltAnalyze and DomainGraph: Analyzing and visualizing exon
768 expression data. *Nucleic Acids Res.* 2010;38(SUPPL. 2).
769 <https://doi.org/10.1093/nar/gkq405>.
- 770 22. Babicki S, et al. Heatmapper: web-enabled heat mapping for all. *Nucleic Acids Res.*
771 2016;44(1):W147–W153.
- 772 23. Steen CB, et al. Profiling cell type abundance and expression in bulk tissues with
773 CIBERSORTx. *Methods in Molecular Biology.* Humana Press Inc.; 2020:135–157.
- 774 24. Li Y, et al. Alterations of specific chromatin conformation affect ATRA-induced
775 leukemia cell differentiation. *Cell Death Dis.* 2018;9(2).
776 <https://doi.org/10.1038/s41419-017-0173-6>.
- 777 25. CZ CELLxGENE Discover. Chan Zuckerberg Initiative [Internet].
778 <https://cellxgene.czscience.com/>.
- 779 26. Corman VM, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time
780 RT-PCR. *Eurosurveillance.* 2020;25(3). [https://doi.org/10.2807/1560-](https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045)
781 [7917.ES.2020.25.3.2000045](https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045).
- 782 27. Dagotto G, et al. Comparison of Subgenomic and Total RNA in SARS-CoV-2-
783 Challenged Rhesus Macaques. [published online ahead of print: 2021].
784 <https://doi.org/10.1128/JVI>.
- 785 28. Kant R, et al. Common laboratory mice are susceptible to infection with the SARS-
786 CoV-2 beta variant. *Viruses.* 2021;13(11). <https://doi.org/10.3390/v13112263>.
- 787 29. Schmid AS, et al. Antibody-based targeted delivery of interleukin-4 synergizes
788 with dexamethasone for the reduction of inflammation in arthritis. *Rheumatology*
789 *(United Kingdom)*. 2018;57(4):748–755. Doi: 10.1093/rheumatology/kex447.
- 790 30. Seehusen F, et al. Neuroinvasion and Neurotropism by SARS-CoV-2 Variants in
791 the K18-hACE2 Mouse. *Viruses.* 2022;14(5). <https://doi.org/10.3390/v14051020>.
- 792 31. Rosales C. Neutrophil: A cell with many roles in inflammation or several cell
793 types? [preprint]. *Front Physiol.* 2018;9(FEB).
794 <https://doi.org/10.3389/fphys.2018.00113>.
- 795 32. Walle L Vande, Lamkanfi M. Inflammasomes: Caspase-1-activating platforms
796 with critical roles in host defense. *Front Microbiol.* 2011;2(JAN).
797 <https://doi.org/10.3389/fmicb.2011.00003>.
- 798 33. Perregaux D, Gabel CA. Interleukin-1 β maturation and release in response to ATP
799 and nigericin. Evidence that potassium depletion mediated by these agents is a
800 necessary and common feature of their activity. *Journal of Biological Chemistry.*
801 1994;269(21):15195–15203.
- 802 34. Gong YN, et al. Chemical probing reveals insights into the signaling mechanism of
803 inflammasome activation. *Cell Res.* 2010;20(12):1289–1305.
- 804 35. Silvin A, et al. Elevated Calprotectin and Abnormal Myeloid Cell Subsets
805 Discriminate Severe from Mild COVID-19. *Cell.* 2020;182(6):1401-1418.e18.
- 806 36. Simard JC, et al. S100A8 and S100A9 induce cytokine expression and regulate the
807 NLRP3 inflammasome via ROS-dependent activation of NF- κ B(1.). *PLoS One.*
808 2013;8(8). <https://doi.org/10.1371/journal.pone.0072138>.
- 809 37. Jacob C, et al. DMSO-treated HL60 cells: a model of neutrophil-like cells mainly
810 expressing PDE4B subtype. *Int Immunopharmacol.* 2002;2(12):1647–1656.
- 811 38. Tang Y, et al. Excessive IL-10 and IL-18 trigger hemophagocytic
812 lymphohistiocytosis-like hyperinflammation and enhanced myelopoiesis. *Journal of*
813 *Allergy and Clinical Immunology.* 2022;150(5):1154–1167.

- 814 39. Xue Y, et al. Cardiopulmonary Injury in the Syrian Hamster Model of COVID-19.
815 *Viruses*. 2022;14(7). <https://doi.org/10.3390/v14071403>.
- 816 40. Vargas F, et al. Intravital imaging of 3 different microvascular beds in SARS-CoV-
817 2-infected mice. *Blood Adv*. 2023;7(15):4170–4181.
- 818 41. Winkler ES, et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes
819 severe lung inflammation and impaired function. *Nat Immunol*. 2020;21(11):1327–
820 1335.
- 821 42. Zhang Y, et al. Neutrophil subsets and their differential roles in viral respiratory
822 diseases [preprint]. *J Leukoc Biol*. 2022;111(6):1159–1173.
- 823 43. Camp J V., Jonsson CB. A role for neutrophils in viral respiratory disease
824 [preprint]. *Front Immunol*. 2017;8(MAY). <https://doi.org/10.3389/fimmu.2017.00550>.
- 825 44. McKenna E, et al. Neutrophils in COVID-19: Not Innocent Bystanders [preprint].
826 *Front Immunol*. 2022;13. <https://doi.org/10.3389/fimmu.2022.864387>.
- 827 45. Lee JS, et al. Immunophenotyping of covid-19 and influenza highlights the role of
828 type i interferons in development of severe covid-19. *Sci Immunol*. 2020;5(49).
829 <https://doi.org/10.1126/sciimmunol.abd1554>.
- 830 46. Sinha S, et al. Dexamethasone modulates immature neutrophils and interferon
831 programming in severe COVID-19. *Nat Med*. 2022;28(1):201–211.
- 832 47. Takeuchi O, Akira S. Pattern Recognition Receptors and Inflammation [preprint].
833 *Cell*. 2010;140(6):805–820.
- 834 48. Israelow B, et al. Mouse model of SARS-CoV-2 reveals inflammatory role of type
835 i interferon signaling. *Journal of Experimental Medicine*. 2020;217(12).
836 <https://doi.org/10.1084/JEM.20201241>.
- 837 49. Broz P, Dixit VM. Inflammasomes: Mechanism of assembly, regulation and
838 signalling [preprint]. *Nat Rev Immunol*. 2016;16(7):407–420.
- 839 50. Hoang TN, et al. Modulation of type I interferon responses potently inhibits SARS-
840 CoV-2 replication and inflammation in rhesus macaques.
841 <https://doi.org/10.1101/2022.10.21.512606>.
- 842 51. Lucas C, et al. Longitudinal analyses reveal immunological misfiring in severe
843 COVID-19. *Nature*. 2020;584(7821):463–469.
- 844 52. Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus
845 in Wuhan, China. *The Lancet*. 2020;395(10223):497–506.
- 846 53. Song X, et al. Little to no expression of angiotensin-converting enzyme-2 on most
847 human peripheral blood immune cells but highly expressed on tissue macrophages.
848 *Cytometry Part A*. [published online ahead of print: February 1, 2020].
849 <https://doi.org/10.1002/cyto.a.24285>.
- 850 54. Nikitina E, et al. Monocytes and macrophages as viral targets and reservoirs
851 [preprint]. *Int J Mol Sci*. 2018;19(9). <https://doi.org/10.3390/ijms19092821>.
- 852 55. Patel AA, Ginhoux F, Yona S. Monocytes, macrophages, dendritic cells and
853 neutrophils: an update on lifespan kinetics in health and disease [preprint].
854 *Immunology*. 2021;163(3):250–261.
- 855 56. Zhou J, et al. Opsonization of malaria-infected erythrocytes activates the
856 inflammasome and enhances inflammatory cytokine secretion by human macrophages.
857 *Malar J*. 2012;11. <https://doi.org/10.1186/1475-2875-11-343>.
- 858 57. Labzin LI, Lauterbach MAR, Latz E. Interferons and inflammasomes: Cooperation
859 and counterregulation in disease [preprint]. *Journal of Allergy and Clinical
860 Immunology*. 2016;138(1):37–46.
- 861 58. Pothlichet J, et al. Type I IFN Triggers RIG-I/TLR3/NLRP3-dependent
862 Inflammasome Activation in Influenza A Virus Infected Cells. *PLoS Pathog*.
863 2013;9(4). <https://doi.org/10.1371/journal.ppat.1003256>.

- 864 59. Kopitar-Jerala N. The role of interferons in inflammation and inflammasome
865 activation [preprint]. *Front Immunol.* 2017;8(JUL).
866 <https://doi.org/10.3389/fimmu.2017.00873>.
867 60. Rashid F, et al. Roles and functions of SARS-CoV-2 proteins in host immune
868 evasion [preprint]. *Front Immunol.* 2022;13.
869 <https://doi.org/10.3389/fimmu.2022.940756>.
870 61. da Silva RP, et al. Circulating Type I Interferon Levels and COVID-19 Severity: A
871 Systematic Review and Meta-Analysis. *Front Immunol.* 2021;12.
872 <https://doi.org/10.3389/fimmu.2021.657363>.
873 62. Smith N, et al. Defective activation and regulation of type I interferon immunity is
874 associated with increasing COVID-19 severity. *Nat Commun.* 2022;13(1).
875 <https://doi.org/10.1038/s41467-022-34895-1>.
876 63. Robertson SE, et al. Expression and alternative processing of IL-18 in human
877 neutrophils. *Eur J Immunol.* 2006;36(3):722–731.
878 64. Mangan MSJ, et al. Targeting the NLRP3 inflammasome in inflammatory diseases
879 [preprint]. *Nat Rev Drug Discov.* 2018;17(8):588–606.
880 65. Rubio-Rivas M, et al. WHO Ordinal Scale and Inflammation Risk Categories in
881 COVID-19. Comparative Study of the Severity Scales. *J Gen Intern Med.*
882 2022;37(8):1980–1987.
883
884

885

Figures & figure legends



886

887

888

889

890

891

892

893

894

895

896

897

898

Figure 1. Increased IFN-I related gene expression in mature COVID-19 neutrophils. The analysis was reduced to include only the samples with the highest purity (cell fraction over 0.65 of neutrophils), as identified by CIBERSORTx. **(A)** Principal component analysis (PCA) of the RNA-seq samples (n = 7 PMNs from HC, n = 10 PMNs from severe COVID-19, n=8 PMNs from mild COVID-19, and n = 6 LDGs from severe COVID-19). **(B)** Ridgeline diagrams depicting the top 20 enriched signal pathways from the genes differentially expressed by PMNs versus LDGs during severe COVID-19: overrepresentation analysis (ORA) using KEGG database and gene-set enrichment analysis (GSEA) according to Reactome database. Both enrichment analyses were made using ExpressAnalyst and are sorted by P-value, obtained from Welch's t-test. **(C)** Heatmap of differentially expressed IFN-related genes in COVID-19 PMNs and LDGs as compared to HC PMNs. RNA sequencing was performed on purified PMNs from healthy controls, mild COVID-19 and severe COVID-19, as well as LDGs from severe COVID-19. The heatmap was clustered by complete linkage and ordered by Spearman's rank. *FC* = fold change.

899





Figure 2. Inflammasome related gene expression and cytokine secretion in PMNs during severe COVID-19. (A-B) Ridgeline diagrams of overrepresentation analyses (ORA) according to KEGG database, depicting the top 10 enriched signaling pathways in PMNs during severe COVID-19 compared to (A) healthy controls and (B) mild COVID-19. (C) IL-1 β and (D) IL-18 levels in 24-h cell culture supernatants from COVID-19 (n = 11 for IL-1 β and 9 for IL-18) and HC PMNs (n =6 for both). (E) IL-1 β and (F) IL-18 levels in 24-h cell culture supernatant from PMNs exposed or non-exposed to purified SARS-CoV-2 viral particles (10 virus particles / PMN) (n = 3). (G) Caspase1 activity in PMNs following a 2-h stimulation with nigericin or purified SARS-CoV-2 viral particles (10 virus particles / PMN). For HC PMNs, n = 9 for mock and nigericin and n = 6 for SARS-CoV-2 exposure. For COVID-19 PMNs, n = 12 for mock and nigericin and n = 9 for SARS-CoV-2 exposure. *p < 0.05 and **p < 0.01. Data presented as mean \pm SD. Tukey's multiple comparisons test for mixed-effect analysis was applied for (G), meanwhile P values for (C-F) were calculated with the Mann-Whitney U-test.

900
901
902
903
904
905
906
907
908
909
910
911
912
913



914
915
916
917
918
919
920
921
922
923
924
925

Figure 3. Comparative neutrophil transcriptomics of COVID-19 and non-COVID-19 patients.

Bar graphs represent the activation levels of selected pathways and processes as identified by neutrophil transcriptomics. The analysis includes IFN- α responses, IL-1 β production, TLR signaling, NLRP3 inflammasomes, and pyroptosis as determined through the Gene Ontology (GO) database. The NOD-like receptor signaling pathway was investigated using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database, and the inflammasome pathway was explored via the REACTOME database. The graphs compare the activation levels of these pathways in healthy controls (HC), non-COVID patients with similar symptoms (COVID-19 negative), and COVID-19 positive individuals. Statistical significance is denoted as follows: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. P values were calculated with Kruskal-Wallis test.





Figure 4. IFN-I primes inflammasome activation while COVID-19 PMNs show defective inflammasome responses *ex vivo*. Isolated HC or COVID-19 PMNs were non-stimulated or stimulated 4h with IFN-I (combination of 2.7×10^4 IU/ml IFN- α and IFN- β) or 20 ng/ml LPS (1st signal), followed by 4h with 2.5 μ M nigericin or purified SARS-CoV-2 (10:1 virus/PMNs) (2nd signal). Then, (A) western blot of pro-IL-1 β (31 kD) and active IL-1 β (17 kD) was performed from HC PMNs supernatant and cell lysates, (B) IL-1 β (n = 5 HC PMN and 9 COVID-19 PMN) and (C) MPO (n = 5 HC PMN and 9 COVID-19 PMN) were measured from supernatants by ELISA. (D-E) Effect of inflammasome inhibitor MCC950 (2 μ g/ml, added simultaneously with nigericin) on IL-1 β secretion in HC (D) and severe COVID-19 PMN (E) supernatant (n = 3). (F) LDH and (G) IL-8 in HC and severe COVID-19 PMN supernatants (n = 3). (H-K) RT-qPCR of selected mRNAs in IFN-I or LPS-primed HC and COVID-19 PMNs (n = 6-8 HC PMN and 7-10 COVID-19 PMN). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; n = 2-4. Data were presented as mean \pm SD. P values calculated with Kruskal-Wallis test for the comparison between treatments by group (HC or COVID-19 PMNs), and Mann-Whitney test for the comparison between HC and COVID-19 PMNs by individual treatment for (B-G), and Two-way ANOVA Tukey's multiple comparisons test for (B, H-K). Data presented as mean \pm SD.

926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941



942
943
944
945
946
947
948
949
950
951
952
953

Figure 5. Correlation analysis between clinical parameters and *ex vivo* PMN inflammasome activation. (A) Spearman's correlation matrix depicting the relationships among clinical parameters and results of *ex vivo* experimentation. For the WHO ordinal scale, the baseline parameters were used. (B-C) Linear regression analysis demonstrating the associations between: (B) Positive association between PMN Caspase1 activity, measured after *ex vivo* nigericin stimulation, and the levels of Calprotectin in the matched patient's peripheral blood; (C) Negative association between *ex vivo* stimulated PMN IL-1β levels (LPS+Nig) and the blood neutrophil count in matched patients at the time of sampling (n=12). LOS = length of stay. WHO = World Health Organization. Min = minimum. Casp1 = caspase1. LPS or IFN + nig = lipopolysaccharide or type I interferon + nigericin *ex vivo* stimulation.




Figure 6. Immature neutrophils express IL-18 in response to inflammasome activation.

(A) Heatmap depicting selected differentially expressed inflammasome related genes from RNA sequencing performed in PMNs from HC, mild and severe COVID-19, as well as severe COVID-19 LDGs. Only the samples with the highest purity, determined by a cell fraction over 0.65 of neutrophils (identified by CIBERSORTx) are included. The heatmap was clustered by complete linkage and ordered by Spearman's rank.

(B) UMAP analysis of the COVID-19 Immune Atlas, which integrates 5 public COVID-19 PBMC single-cell transcriptomics datasets, created using CELLxGENE. (Top) UMAP showing the clustering of CD16⁺ cells (mature, FCGR3B expressing cells) and CD66b⁺ cells (immature, CEACAM8 expressing cells). Each dot represents a single cell colored according to the expression level of a selected gene. The color scale ranges from green (low expression) to purple (high expression). (Bottom) Pie chart summarizing the percentage of mature (black) and immature (blue) cells in the dataset.

(C) The fraction of mature and immature neutrophils cells expressing inflammasome related genes identified in Figure 7B are shown in a bar graph. For each gene, the proportion of expressing cells is shown in light blue, while the proportion of negative or not-expressing cells is shown in gray. Zoomed-in bar graph depicts the proportion of mature and immature cells expressing each gene.

(D-G) Isolated COVID-19 LDGs or HL-60 cells (differentiated for 5 days with 1% DMSO) were non-stimulated or stimulated 4h with IFN-I or LPS (1st signal), followed by 4h with nigericin (2nd signal) in

954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972

973 the presence or absence of inflammasome inhibitors MCC950 or YVAD as previously. Secretion of (D,
974 F) IL-1 β and (E, G) IL-18 were measured from the supernatants by ELISA (n = 2 for LDGs and 3-5 for
975 HL-60).
976 *p < 0.05 and **p < 0.01. P values calculated with Kruskal-Wallis test. Data presented as mean \pm SD.
977 (H) Volcano plot of differentiated vs undifferentiated HL-60 cells gene expression from GSE93996, with
978 inflammasome related genes marked in blue. Only significant DE genes are shown (adjusted p value <
979 0.05).




Figure 7. Neutrophils of SARS-CoV-2 infected mice display increased caspase1 activation ability that is dependent on IFN-I.

Female BALB/c mice were intranasally inoculated with 5×10^5 TCID50 SARS-CoV-2 MaVie strain or PBS as control. Lungs were harvested at 2 and 4 dpi and Ly-6G⁺ neutrophils isolated based on positive selection with magnetic beads. RNA was isolated and subjected to transcriptomic analysis by RNA-seq. (A) Principal component analysis (PCA) of the PBS-inoculated control and SARS-CoV-2 infected mice lung neutrophil RNA-seq samples. (B) Heatmap of the top DEGs. (C) Volcano plots of DEGs between neutrophils isolated from SARS-CoV-2 infected mice versus uninfected PBS-inoculated mice. Blue points represent significant terms (adjusted p-value < 0.05), while smaller gray points represent non-significant terms. Relevant inflammasome and interferon related genes are shown with larger and darker blue points. (D) Caspase1 activity in isolated mice neutrophils following a 2-h stimulation with nigericin was assessed by a bioluminescence method (Caspase-Glo® 1 Inflammasome Assay). (E-G) Mice were intraperitoneally inoculated with 250 μ g anti-IFNAR or IgG1 isotype control directly after infection with SARS-CoV-2 and lung neutrophils isolated at 2 dpi (including also intranasally PBS-inoculated control mice without intraperitoneal injection).


980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995

996 (E) Caspase1 activity was assessed following a 2-h stimulation with nigericin by bioluminescence
997 method.
998 (F-G) RNA was isolated from isolated neutrophils and fold change mRNA expressions of (C) Caspase1
999 (Casp1) and (D) IL-1 β (IL1b) in isotype control and anti-IFNAR treated infected mice as compared to
1000 mock-infected control mice assessed by RT-qPCR.
1001 DEG = differentially expressed genes.
1002 *p < 0.05, and **p < 0.01. P values for D, E and H panels were calculated with ordinary one-way ANOVA
1003 using Tukey's multiple comparisons. Welch's t-test was used for panels F and G. Data presented as mean
1004 \pm SD.


1005

Supplementary figure legends

A



B



1006

1007

1008

1009

1010

1011

1012

1013

1014

1015

1016

1017


1018

Supplementary Figure 1. Comparison of gene expression in granulocyte populations of COVID-19 patients using RNA-seq analysis.

(A) Deconvoluted RNA-seq data. The cellular composition in isolated PMN and LDG fractions was estimated using CIBERSORTx through the identification of cell populations based on RNA-seq. The bar plots in the figure represent the cell composition of each RNA-seq sample, offering insights on sample purity.

(B) Heatmap of the top 118 differentially expressed genes between PMNs from healthy controls, mild and severe COVID-19, as well as LDGs from severe disease, identified by unsupervised ICGS analysis based on correlation, using AltAnalyze software. IFN-related genes, identified by GENESHOT, are shown in bold.

1019



1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032


Supplementary Figure 2. Enriched differentially expressed genes and pathways in severe COVID-19 PMNs and LDGs.

(A-B) Volcano plots of DEGs between severe COVID-19 PMNs versus (C) HC PMNs and (D) severe COVID-19 LDGs.

(C-D) Volcano plots of enriched gene sets in severe COVID-19 PMNs versus (A) HC PMNs and (B) severe COVID-19 LDGs, using KEGG database. Each point represents a single gene set, where the x-axis measures its odds ratio, while the y-axis shows its $-\log_{10}(p\text{-value})$.


(E-F) Volcano plots of (E) severe COVID-19 PMNs versus mild COVID-19 PMNs and (F) mild COVID-19 PMNs vs HC PMN.

For all panels, blue points represent significant terms (adjusted p-value < 0.05), while smaller gray points represent non-significant terms. *DEG* = differentially expressed genes.



1033
1034
1035
1036
1037
1038
1039

Supplementary Figure 3. Differential expression of interferon and inflammasome related genes in PMNs during COVID-19. RNA was extracted from isolated HC PMNs (n = 8-13) versus severe COVID-19 PMNs (n = 29-32) and subjected to comparative RT-qPCR using specific primers for OAS1, OAS2, IFIT1, IFI16, caspase1, caspase5, IL1B, NLRC4, NLRC5, NLRP3 and NAIP. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. P values calculated with Mann-Whitney U-test. Data presented as mean ± SD.



Supplementary Figure 4. Ex vivo stimulation of isolated PMNs.


(A) IL-18 (n = 2-3 HC PMN and 3 COVID-19 PMN) was measured from supernatants by ELISA following LPS or IFN-I priming (4-h) and subsequent nigericin activation (4-h).

(B-C) Effect of different inflammasome specific inhibitors in cytokine secretion. (A) Effect of inflammasome inhibitor MCC950 (2 μg/ml) and YVAD (20 μg/ml) on LPS or IFN-I primed (4-h) and nigericin activated (4-h) IL-1β secretion in the supernatant of healthy control PMNs (n = 8). (B-C) Effect of inflammasome inhibitor MCC950 (2 μg/ml, added simultaneously with nigericin) on LPS or IFN-I primed (4-h) and nigericin activated (20-h) (B) IL-1β and (C) IL-18 secretion in the supernatant of healthy control PMN (n = 3).

(D) Gene expressions in HC and COVID-19 PMNs after LPS or IFN-I stimulation. A comparison of gene expression in isolated healthy control PMNs versus COVID-19 PMNs after *ex vivo* stimulation with LPS or IFN-I. Extracted RNA was subjected to comparative RT-qPCR using specific primers for NLRP3, NLRP4, NAIP and CASP5 (n = 4-8 for HC PMN and 6-9 for COVID-19 PMN). *p < 0.05. Two-way ANOVA with Tukey's multiple comparison test was applied. Data were presented as mean ± SD.


*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. P values calculated with Kruskal-Wallis test. Data presented as mean ± SD. IFN = interferon type I, LPS = lipopolysaccharide, Nig = nigericin, YVAD = tetrapeptide caspase1 inhibitor Tyr-Val-Ala-Asp.

1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057



1058
1059
1060
1061
1062
1063
1064
1065

Supplementary Figure 5. Expression of inflammasome related genes in mature and immature neutrophils from COVID-19 PBMCs. The fraction of mature and immature neutrophils cells expressing 17 inflammasome related genes identified in Figure 7B (shown in black and blue, respectively) are shown in a bar graph. For each gene, the proportion of expressing cells is shown in light blue, while the proportion of negative or not-expressing cells is shown in gray. Zoomed-in bar graph depicts the proportion of mature and immature cells expressing each gene.




1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079

Supplementary Figure 6. Neutrophil accumulation in the lungs correlates with viral loads in SARS-CoV-2 infected mice. Female BALB/c mice were intranasally inoculated with 5×10^5 TCID₅₀ SARS-CoV-2 MaVie strain or PBS as control and euthanized at 2 dpi or 4 dpi. (A) RNA was isolated from lungs and subjected to RT-qPCR targeting viral subE and GAPDH as housekeeping gene. The relative expression of subE was measured using the comparative Ct method as compared to mock-infected control (in which subE was undetectable but set to 40 Ct) **** $p < 0.0001$. P values calculated with Welch's t-test. (B) Quantification based on morphometric analysis that determines the area of immunolabelling for SARS-CoV-2 nucleoprotein in relation to total tissue area. *** $p < 0.001$. P values calculated with Welch's t-test. Black line represents the mean. (C) Quantification of Ly-6G based on morphometric analysis that determines the area of immunolabelling for Ly6G in relation to total tissue area in mock-infected controls. **** $p < 0.0001$. P values calculated with ordinary one-way ANOVA using Tukey's multiple comparisons test. Black line represents the mean.

1080 (D) Left column: immunohistochemistry for SARS-CoV-2 nucleoprotein; right column:
1081 immunohistochemistry for Ly6G (neutrophil marker), hematoxylin counterstain. Bars = 500 μ m (large
1082 images) and 50 μ m (insets).
1083 At 2 dpi (top), the arrow points at a bronchus with viral antigen expression in epithelial cells. A close-up
1084 of the bronchus (bottom; B: bronchial lumen) shows degenerated and slough off antigen positive epithelial
1085 cells. Adjacent alveoli exhibit viral antigen expression in typeI (arrowhead) and typeII (arrow)
1086 pneumocytes. The overview (top) shows neutrophils between the infected bronchial (arrow) epithelial
1087 cells, in parenchymal areas (arrowhead; right inset) and in capillaries (arrowheads). A close-up of the
1088 bronchus (bottom; B: bronchial lumen) highlights numerous neutrophils between degenerate (arrowheads)
1089 epithelial cells.
1090 At 4 dpi (middle), there are focal areas with antigen expression in alveolar epithelial cells and infiltrating
1091 macrophages. Neutrophils are present among the infiltrating cells (arrow) as individual cells (inset:
1092 arrows) or in aggregates (inset: arrowhead).
1093 The bottom shows the lung of a mock-infected control animal. There is no viral antigen expression.
1094 Staining for Ly6G depicts individual neutrophils in larger vessels (inset: arrow) or in capillaries (inset:
1095 arrowheads).
1096

1097



Supplementary Figure 7. Dynamics of animal weight and impact of α -IFNAR treatment in SARS-CoV-2 infected mice. Female BALB/c mice were intranasally inoculated with 5×10^5 TCID50 SARS-CoV-2 MaVie strain or PBS as control.

(A) Daily tracking of animal weight performed throughout the experiment ($n = 8$ for SARS-CoV-2 infected animals, $n = 2$ for PBS-inoculated animals). The weights of the mice euthanized at 2 dpi ($n = 26$) did not show significant differences and are not reported.

(B-C) Mice were intraperitoneally inoculated with 250 μ g anti-IFNAR or IgG1 isotype control directly after infection with SARS-CoV-2 and lung neutrophils isolated at 2 dpi (including also intranasally PBS-inoculated control mice without intraperitoneal injection)

(B) RNA was isolated from mouse lungs and subjected to RT-qPCR targeting the replication-intermediate subgenomic E gene and GAPDH as housekeeping gene. RNA levels were assessed based on cycle threshold Ct levels. The expression levels of the target gene SubE were measured and normalized to GAPDH levels using the comparative Ct method ($\Delta\Delta Ct$). The fold change values were calculated by the formula $2^{-(\Delta\Delta Ct)}$, representing the relative gene expression compared to the PBS mock-infected control (in which subE was undetectable but set to 40 Ct). No significant differences are seen between the two groups, assessed with Welch's t-test.

(C) Histological features, viral antigen expression and extent of neutrophil influx and damage in the lung of SARS-CoV-2 infected BALB/C mice after isotype control and anti-IFNAR treatment at 2dpi.

Left column: Control isotype treated mice; right column: anti-IFNAR treated mice. HE stain (top layer) and immunohistology, hematoxylin counterstain (all other images). Bars: 250 μ m (overview images) and 25 μ m (insets).

In control isotype treated mice, the lung exhibits degeneration and loss of bronchial and bronchiolar epithelial cells (HE stain: arrowhead; right inset), with mild inflammatory infiltration. The parenchyma exhibits focal areas of increased cellularity, with typeII pneumocyte activation and occasional degenerate

1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122

1123 alveolar epithelial cells (arrows; left inset: degenerate cells (arrowhead) and infiltrating neutrophil
1124 (arrow)). Staining for SARS-CoV-2 NP confirms epithelial cell infection in bronchus (arrowhead; right
1125 inset) and alveoli (arrow; left inset). Right inset: Viral antigen expression is seen in intact and sloughed
1126 off, degenerate epithelial cells. Left inset: Viral antigen expression is seen in both typeI (small arrowhead)
1127 and typeII (small arrow) pneumocytes; there are also degenerate positive cells (large arrowhead).
1128 Neutrophils (Ly6G+) are located within focal parenchymal areas of increased cellularity (arrows; left
1129 inset: arrowheads) and present between degenerate bronchial epithelial cells (arrowhead; right inset:
1130 arrowhead). Staining for histone H3 shows neutrophil degeneration/NETosis in parenchymal areas
1131 (arrow; left inset: arrowheads) and associated with degenerate epithelial cells (arrowhead; right inset:
1132 positive reaction between sloughed off epithelial cells (arrow) and between the intact epithelial layer
1133 (arrowhead)).
1134 In anti-IFNAR treated animals, the lung exhibits degeneration and loss of bronchial and bronchiolar
1135 epithelial cells (arrowhead; right inset: arrows), with mild inflammatory infiltration and individual
1136 neutrophils between intact and sloughed off degenerate epithelial cells (right inset: arrowheads). The
1137 parenchyma exhibits focal areas of increased cellularity, with typeII pneumocyte activation and occasional
1138 degenerate alveolar epithelial cells (arrows; left inset: degenerate cells (arrow) and infiltrating neutrophils
1139 (arrowhead). Staining for SARS-CoV-2 NP shows epithelial cell infection in bronchioles (arrowhead;
1140 right inset) and alveoli (arrow; left inset). Right inset: Viral antigen expression is seen in intact and
1141 sloughed off, degenerate epithelial cells. Left inset: Viral antigen expression is seen in pneumocytes
1142 (arrow) and infiltrating macrophages (arrowheads). Neutrophils (Ly6G+) locate within focal parenchymal
1143 areas of increased cellularity (arrows; left inset) and are present between intact (inset: arrowhead) and
1144 degenerate epithelial cells (arrowhead; right inset: arrow). Staining for histone H3cit shows neutrophil
1145 degeneration/NETosis in parenchymal areas (arrow; left inset) and associated with degenerate epithelial
1146 cells (arrowhead; right inset: positive reaction between sloughed off epithelial cells (arrow) and between
1147 the intact epithelial layer (arrowhead)).
1148 *Dpi*= days post infection; *NP* = nucleoprotein.
1149

1150
1151
1152
1153

Tables & table legends

Table 1. Clinical parameters of hospitalized patients (n=34).

| Parameter | Range (Mean \pm SD) or ratio |
|--|--------------------------------|
| Age (years) | 22 - 80 (58.41 \pm 13.63) |
| Gender (male:female) | 23:11 |
| Hospitalization (days) | 3 - 38 (12 \pm 8.63) |
| WHO Ordinal scale for Clinical improvement: Baseline | 1 - 6 (4 \pm 1.07) |
| WHO Ordinal scale for Clinical improvement: Worst | 2 - 8 (4 \pm 1.42) |
| Deaths (count/total) | 1/34 |
| ICU (count/total) | 9/34 |
| Corticosteroid use (count/total) | 13/34 |
| Length of stay in ICU (days) | 1 - 27 (7.38 \pm 9.49) |
| Max CRP (mg/L) | 6 - 466 (159.56 \pm 104.06) |
| Min lymphocyte count (E ⁹ /L) | 0.08 - 2.02 (0.79 \pm 0.42) |
| Max neutrophil count (E ⁹ /L) | 1.08 - 29.86 (7.85 \pm 5.73) |
| Sampling day neutrophil count (E ⁹ /L) | 0.64 - 20.52 (5.65 \pm 3.95) |

1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165

The World Health Organization (WHO) Ordinal Scale for clinical improvement is a tool designed specifically to assess and measure the progression and clinical improvement of patients (65). COVID-19 scoring: 1= no limitations of activity, 2= limitations of activity, 3= no oxygen therapy, 4= oxygen by mask or nasal cannulae, 5= non-invasive ventilation or high-flow oxygen, 6= invasive mechanical ventilation without other organ support, 7= invasive mechanical ventilation with other organ support, 8= dead. The baseline score represents the timepoint of the first laboratory sample taken, serving as a reference point for measuring improvement and establishing a starting point for comparison. In contrast, the worst score represents the most severe or critical state of the disease. None of the patients whose samples were used for RNA-seq underwent corticosteroid treatment. *Abbreviations: WHO= World Health Association. ICU = Intensive Care Unit. CRP = C reactive protein. Min = minimum. Max = maximum.*

1166
1167

Supplementary Table S1. qPCR primer sequences: gene-specific forward and reverse primers.

| Gene | Forward primer | Reverse primer |
|--------------|------------------------|--------------------------|
| AIM2 | GGCCCAGCAGGAA TCTATCAG | GAAGGGCTTCTTTGCTTTCAGTAC |
| NAIP | AAGGGATTGTTGACATAACGGG | CAGCCGTAGTTCTTCGTAAGC |
| NLRC5 | ACAGCATCCTTAGACACTCCG | CCTTCCCAAAAAGCACGGT |
| IL1B | CACATGGGATAACGAGGCTT | TCCAGCTGTAGAGTGGGCTT |
| CASP1 | GCTTTCTGCTCTCCACACC | TCCTCCACATCACAGGAACA |
| CASP4 | CAAGAGAAGCAACGTATGGCA | AGGCAGATGGTCAAACCTCTGTA |
| CASP5 | TTCAACACCACATAACGTGTCC | GTCAAGGTTGCTCGTTCTATGG |
| IFI16 | TCCTCAGATGCCTCCATCAAC | CAGGTCAGTCTTCAGTCTTGGT |
| IFIT5 | TAAAAAAGGCCTTGGAGGTG | CCAGGTCTGTGTAGGCAAAT |
| IRF7 | GCTGGACGTGACCATCATGTA | GGGCCGTATAGGAACGTGC |
| IFIT1 | GCGCTGGGTATGCGATCTC | CAGCCTGCCTTAGGGGAAG |
| IFI6 | GGTCTGCGATCCTGAATGGG | TCACTATCGAGATACTTGTGGGT |
| OAS1 | TGTCCAAGGTGGTAAAGGGTG | CCGGCGATTAACTGATCCTG |
| OAS2 | CTCAGAAGCTGGGTTGGTTTAT | ACCATCTCGTCGATCAGTGTC |
| GAPDH | TTGGCTACAGCAACAGGGTG | GGGGAGATTCAGTGTGGTGG |

1168
1169

1170
1171
1172

Supplementary Table S2. Histological changes as well as SARS-CoV-2 nucleoprotein and RNA expression in female BALB/C mice infected with SARS-CoV-2.

A. Experiment 1. Infected animals were euthanized and examined at 2 and 4 days post infection.

| Infection, dpi [Animal no] | Histological changes, viral antigen and Ly6G expression ¹ in lungs | Viral subE (and GAPDH) RNA Cts ² |
|---|---|---|
| 5 x 10⁵ PFU, 2 dpi [1.1.1] | HE: bronchioles with abundant degen EC (in place and sloughed off); parenchymal areas with type II pn activation, occ degen AEC and increased cellularity vAg: extensive expression in bronchus/bronchioles (almost all BEC, some also degen); most alveoli with pos AEC Ly6G: increase in NL in lumen of vessels and capillaries; NL in lumen of bronchioles and alveoli (partly degen) and in association with degen BEC | 15.12 (13.47) |
| 5 x 10⁵ PFU, 2 dpi [1.1.2] | HE: bronchioles with abundant degen EC (in place and sloughed off); parenchymal areas with type II pn activation, occ degen AEC and increased cellularity vAg: extensive expression in bronchus/bronchioles (almost all BEC, some also degen); most alveoli with pos AEC Ly6G: increase in NL in lumen of vessels and capillaries, NL in lumen of bronchioles and alveoli (partly degen) and in association with degen BEC | 15.92 (13.79) |
| 5 x 10⁵ PFU, 2 dpi [1.1.3] | HE: bronchioles with abundant degen EC (in place and sloughed off); parenchymal areas with type II pn activation, occ degen AEC and increased cellularity vAg: extensive expression in bronchus/bronchioles (almost all BEC, some also degen); most alveoli with pos AEC Ly6G: increase in NL in lumen of vessels and capillaries, NL in lumen of bronchioles and alveoli (partly degen) and in association with degen BEC | 15.56 (13.83) |
| 5 x 10⁵ PFU, 2 dpi [1.1.4] | HE: bronchioles with abundant degen EC (in place and sloughed off); parenchymal areas with type II pn activation, occ degen AEC and increased cellularity vAg: extensive expression in bronchus/bronchioles (almost all BEC, some also degen); most alveoli with pos AEC Ly6G: increase in NL in lumen of vessels and capillaries, NL in lumen of bronchioles and alveoli (partly degen) | 16.33 (14.81) |
| 5 x 10⁵ PFU, 4 dpi [1.2.1] | HE: one bronchiole with degen EC (in place and sloughed off), others unaltered; large parenchymal area with extensive type II pn activation, degen AEC and increased cellularity (leukocytes incl NL) vAg: some bronchioles with extensive expression (almost all BEC, some also degen), others with a few individual or no pos BEC; patches of alveoli with pos AEC (within and outside affected areas) Ly6G: some increase in NL in lumen of vessels and capillaries, NL in lumen of bronchioles and alveoli in affected area (partly degen) | 31.68 (11.64) |
| 5 x 10⁵ PFU, 4 dpi [1.2.2] | HE: bronchioles with a few degen EC (in place or sloughed off), others unaltered; small parenchymal area with type II pn activation, degen AEC and increased cellularity (leukocytes incl NL) vAg: some bronchioles with several (partly degen) pos BEC, most with a few individual or no pos BEC; patches of alveoli with pos AEC (within and outside affected area) Ly6G: some increase in NL in lumen of vessels and capillaries, a few NL in lumen of bronchioles and alveoli in affected area (partly degen) | 31.86 (11.78) |
| 5 x 10⁵ PFU, 4 dpi [1.2.3] | HE: bronchioles with a few degen EC (in place or sloughed off), others unaltered; small parenchymal area with type II pn activation, degen AEC and increased cellularity (leukocytes incl NL) vAg: some bronchioles with several (partly degen) pos BEC, most with a few individual or no pos BEC; patches of alveoli with pos AEC (within and outside affected area) Ly6G: some increase in NL in lumen of vessels and capillaries, a few NL in lumen of bronchioles and alveoli in affected area (partly degen) | 31.33 (11.71) |
| 5 x 10⁵ PFU, 4 dpi [1.2.4] | HE: bronchioles with rare degen EC, most unaltered; parenchymal area with type II pn activation, degen AEC and increased cellularity (leukocytes incl NL) vAg: some bronchioles with a few to several (partly degen) pos BEC, most with a few individual or no pos BEC; patches of alveoli with pos AEC (within and outside affected area) Ly6G: some increase in NL in lumen of vessels and capillaries, a few NL in lumen of bronchioles and alveoli in affected area (partly degen) | 35.02 (11.89) |
| PBS (control), 2 dpi [1.3.1] | Lung: NHA vAg: neg Ly6G: a few individual NL in lumen of vessels and capillaries | n.d., set to 40 (13.65) |
| PBS (control), 2 dpi [1.3.2] | Lung: NHA vAg: neg Ly6G: a few individual NL in lumen of vessels and capillaries | n.d., set to 40 (15.66) |

| | | |
|--|---|----------------------------|
| PBS (control), 2 dpi [1.3.3] | Lung: NHA vAg: neg Ly6G: a few individual NL in lumen of vessels and capillaries | n.d., set to 40 (14.32) |
| PBS (control), 2 dpi [1.3.4] | Lung: NHA vAg: neg Ly6G: a few individual NL in lumen of vessels and capillaries | n.d., set to 40 (14.57) |

1173
1174
1175

B. Experiment 2. Infected animals were euthanized and Ly6G neutrophils isolated from lungs at 2 and 4 days post infection.

| |
|---|
| Infection, dpi [Animal no] |
| 5 x 10⁵ PFU, 2 dpi [2.1.1] |
| 5 x 10⁵ PFU, 2 dpi [2.1.2] |
| 5 x 10⁵ PFU, 2 dpi [2.1.3] |
| 5 x 10⁵ PFU, 2 dpi [2.1.4] |
| |
| 5 x 10⁵ PFU, 4 dpi [2.2.1] |
| 5 x 10⁵ PFU, 4 dpi [2.2.2] |
| 5 x 10⁵ PFU, 4 dpi [2.2.3] |
| 5 x 10⁵ PFU, 4 dpi [2.2.4] |
| |
| PBS (control), 2 dpi [2.3.1] |
| PBS (control), 2 dpi [2.3.2] |
| PBS (control), 2 dpi [2.3.3] |
| PBS (control), 2 dpi [2.3.4] |

1176
1177
1178
1179

C. Experiment 3. Infected animals were treated with control isotype or IFNAR blocking antibody prior to euthanization and examination at 2 days post infection.

| Infection, treatment [Animal no, sex, age] | Histological changes, viral antigen (vAg), Ly6G and histone H3 expression¹ in lungs | Viral subE (and GAPDH) RNA Cts² |
|---|--|---|
| 5 x 10⁵ PFU, control isotype [3.1.1] | HE: bronchus and connected bronchiole with abundant degen EC (in place or sloughed off); endothelial cell activation in adjacent muscular veins, with some leukocyte adhesion; adjacent parenchymal areas with type II pn activation, occ degen AEC and increased cellularity vAg: extensive expression in bronchus/bronchioles (almost all BEC, also degen), and large adjacent areas of alveoli with pos AEC Ly6G: increase in NL in lumen of vessels and capillaries in affected areas, NL in lumen of bronchioles and alveoli (partly degen) H3: pos reaction in areas with degen NL (lumen of bronchioles, affected alveoli) | 14.75 (12.63) |
| 5 x 10⁵ PFU, control isotype [3.1.2] | HE: some bronchioles with abundant degen EC (in place or sloughed off); endothelial cell activation in some adjacent vessels; (adjacent) parenchymal areas with type II pn activation, occ degen AEC and increased cellularity vAg: extensive expression in some bronchioles (almost all BEC, also degen), large (adjacent) areas of alveoli with pos AEC Ly6G: mild increase in NL in lumen of vessels and capillaries in affected areas, NL in lumen of bronchioles and alveoli (partly degen) H3: pos reaction in areas with degen NL (lumen of bronchioles, affected alveoli) | 16.61 (11.54) |

| | | |
|---|--|----------------------------|
| 5 x 10⁵ PFU, control isotype [3.1.3] | HE: bronchioles with abundant degen EC (in place or sloughed off); endothelial cell activation in some muscular veins, with leukocyte rolling and subendothelial infiltration (vasculitis), other vessels packed with leukocytes; (adjacent) parenchymal areas with type II pn activation, occ degen AEC and increased cellularity vAg: extensive expression in bronchioles (patches of BEC to almost all BEC, also degen), large (adjacent) areas of alveoli with pos AEC Ly6G: mild increase in NL in lumen of vessels and capillaries in affected areas, NL in lumen of bronchioles and alveoli (often degen) H3: extensive pos reaction in areas with degen NL (lumen of bronchioles, affected alveoli) | 16.00 (12.71) |
| 5 x 10⁵ PFU, control isotype [3.1.4] | HE: bronchus and bronchioles with abundant degen EC (in place or sloughed off); endothelial cell activation in some muscular veins, with leukocyte rolling and pv infiltration; (adjacent) parenchymal areas with type II pn activation, occ degen AEC and increased cellularity vAg: extensive expression in bronchioles (patches to almost all BEC, also degenerate), large (adjacent) areas of alveoli with pos AEC Ly6G: mild increase in NL in lumen of vessels and capillaries in affected areas, NL in lumen of bronchioles and alveoli (partly degenerate) H3: pos reaction in areas with degen NL (lumen of bronchioles, affected alveoli); most extensive in alveoli | 15.07 (13.83) |
| 5 x 10⁵ PFU, anti-IFNAR [3.2.1] | HE: bronchus and connected bronchiole with abundant degen EC (in place or sloughed off); endothelial cell activation in muscular veins, with some leukocyte adhesion; patchy parenchymal areas with type II pn activation, occ degen AEC and increased cellularity vAg: extensive expression in bronchioles (abundant to almost all BEC, also degen), and large areas of alveoli with pos AEC Ly6G: increase in NL in lumen of vessels and capillaries in affected areas, NL in lumen of bronchioles and alveoli (partly degen) H3: pos reaction in areas with degen NL (lumen of bronchioles, affected alveoli) | 13.98 (12.44) |
| 5 x 10⁵ PFU, anti-IFNAR [3.2.2] | HE: bronchioles with occ degen EC (in place or sloughed off); endothelial cell activation in muscular veins, with some leukocyte adhesion; parenchymal areas with type II pn activation, occ degen AEC and increased cellularity vAg: extensive expression in bronchus/bronchioles (almost all BEC, also degen), and large areas of alveoli with pos AEC Ly6G: increase in NL in lumen of vessels and capillaries in affected areas, NL in lumen of bronchioles and alveoli (partly degen) H3: pos reaction in areas with degen NL (lumen of bronchioles, affected alveoli) | 14.90 (13.12) |
| 5 x 10⁵ PFU, anti-IFNAR [3.2.3] | HE: infected bronchus with a few degen EC (in place); mild endothelial cell activation in some adjacent vessels; (adjacent) parenchymal areas with type II pn activation and increased cellularity vAg: a few individual EC in bronchus and some bronchioles, one with all EC pos, adjacent large patches of alveoli with pos AEC Ly6G: increase in individual NL in lumen of vessels and capillaries (mainly in affected areas), a few NL in lumen and between EC of infected bronchiole, and in alveoli in affected areas H3: rare pos reaction in alveoli | 28.79 (14.09) |
| 5 x 10⁵ PFU, anti-IFNAR [3.2.4] | HE: infected bronchioles with variable amount of degen EC (in place or sloughed off); endothelial cell activation in some vessels, with leukocyte rolling and pv infiltration; (adjacent) parenchymal areas with type II pn activation, occ degen AEC and increased cellularity vAg: bronchus and bronchioles with individual, patches of to almost all BEC pos (also degen) and cell free viral Ag in lumen, large (adjacent) areas of alveoli with pos AEC (also degen) Ly6G: increase in NL in lumen of vessels and capillaries in affected areas, NL in lumen of bronchioles and alveoli (partly degen) H3: extensive pos reaction in areas with degen NL (lumen of bronchioles, affected alveoli) | 13.54 (13.33) |
| PBS (control), none [3.3.1] | Lung: NHA vAg: neg Ly6G: a few individual NL in lumen of vessels and capillaries | n.d., set to 40 (10.20) |
| PBS (control), none [3.3.2] | Lung: NHA vAg: neg Ly6G: a few individual NL in lumen of vessels and capillaries | n.d., set to 40 (11.04) |
| PBS (control), none [3.3.3] | Lung: NHA vAg: neg Ly6G: a few individual NL in lumen of vessels and capillaries | n.d., set to 40 (14.06) |
| PBS (control), none [3.3.4] | Lung: NHA vAg: neg Ly6G: a few individual NL in lumen of vessels and capillaries | n.d., set to 40 (13.70) |

1180 The age of the infected animals were 9 weeks in experiment 1 and 8 weeks in experiment 3; alv – alveolar;
1181 BEC – bronchiolar epithelial cells; degen – degenerate (this also includes apoptotic and/or necrotic); EC
1182 – epithelial cells; F – female; HE – histological features assessed in a hematoxylin-eosin stained section;
1183 incl – including; M – male; neg – negative; NHA – no histological abnormality; NL – neutrophilic
1184 leukocytes (i.e. neutrophils); occ – occasional; pc – pneumocytes; pos – positive; pv – perivascular; vAg
1185 – viral antigen; we – weeks; n.d. – not detected

1186 ¹ Viral antigen and Ly6G expression determined by immunohistochemistry.

1187 ² Obtained RT-qPCR cycle threshold values (Cts) for viral subgenomic E gene (subE) as a measure of
1188 viral replication and GAPDH mRNA as the housekeeping gene. As expected, for PBS control animals no
1189 Ct value for viral subE was obtained. The subE Ct for control animals was set to the detection limit of 40
1190 to facilitate fold change calculations presented in Figure 8A and Supplementary Fig. 5B.